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Abstract 
I 
Ill 
Reactive nitrogen and oxygen species are produced under physiological 
conditions. However, excess of these radicals may damage cellular lipids, proteins 
and nucleic acids. These reactive species have been implicated in many disease 
conditions including chronic inflammation, atherosclerosis, rheumatoid arthritis, 
some neurodegenerative diseases and systemic lupus erythematosus. Systemic 
lupus erythematosus and rheumatoid arthritis are autoimmime diseases with 
complex etiology and pathogenesis. The abnormal level of nitrotyrosine detected in 
tissues affected by above diseases have been attributed to peroxynitrite-mediated 
hypemitration of tyrosine residues in proteins. Peroxynitrite is a potent oxidant as 
well as nitrating agent and has in vivo existence. It is formed when nitric oxide 
reacts with superoxide radical. Peroxynitrite is a powerful pro-inflammatory 
substance and may increase vascular permeability in inflamed tissues. 
In this doctoral thesis, physico-chemical and immunological studies have 
been carried out on histones modified by peroxynitrite with an objective of 
studying the possible role of oxidatively nitrated proteins in the 
initiation/progression of systemic lupus erythematosus and rheumatoid arthritis. 
Analysis of UV absorption profile of peroxynitrite-modified HI, H2A, 
H2B and H3 histones revealed peak shift to higher wavelength and 
hyperchromicity at 276 nm compared to native histones. Furthermore, in case of 
modified-histones an additional peak was observed at 420 nm which corresponds 
to nitrotyrosine because a standard solution of 3-nitrotyrosine had given a similar 
peak under our experimental conditions. The hyperchromicity observed in 
peroxynitrite-modified histones' samples might be due to nitration of tyrosine 
residues which ultimately enhances the molar absorptivity compared to native 
histones. HPLC analysis confirmed generation of nitrotyrosine in peroxynitrite-
modified histones. Fluorescence studies on native and peroxynitrite-modified 
histones showed significant decrease in the emission intensity of modified-
histones. This quenching in emission intensity might be the consequence of 
introduction of nitro group in tyrosine residues. 
The structural changes in peroxynitrite-modified histones were also studied 
by l-anilinonaphthalene-8-sulfonic acid (ANS) - binding to native and modified-
histones' samples. Upon modification by peroxynitrite the hydrophobic 
IV 
clusters/patches in histones were exposed for ANS binding and it lead to increase 
in ANS fluorescence intensity and blue shift in emission wavelength. The observed 
blue shift could be the reflection of change in histones' structure fi-om natively 
unfolded state to a partially folded form due to peroxynitrite-mediated nitration. 
Far-UV CD and FT-IR studies on native and peroxynitrite-modified histones 
concluded that the unfolded structure of histones converted into ordered structure 
after treatment with peroxynitrite. Melting studies demonstrated that interaction of 
histones with peroxynitrite caused increase in the thermal stability of 
peroxynitrite-modified histones compared to control. The stability of 
peroxynitrite-modified histones could be the consequence of formation of cross 
links and/or disulphide bridge(s). Furthermore, the appearance of ordered structure 
in modified-histones may also contribute to the observed rise in melting 
temperature. Results of polyacrylamide gel electrophoresis showed formation of 
high molecular weight species in peroxynitrite-treated histones. It may be linked to 
cross-linking and oligomerization of histones by the oxidative and nitrosative 
action of peroxynitrite. 
Histones are conserved proteins and weak immunogen. However, they 
exhibit strong immunogenicity after acetylation and nitration. Rabbits challenged 
with peroxynitrite-modified H2A histone induced high titre antibodies; an 
indication that modification has generated powerfiil immunogenic epitopes. IgG 
antibodies purified from immune sera showed preferential binding with the 
immunogen as revealed by inhibition ELISA. The poly specific nature of induced 
antibodies was established by its binding with peroxynitrite-modified forms of 
H2B, HI, H3 histones, HSA, proteins rich in tyrosine residues and nucleic acids. 
Mobility shift assay carried out in polyacrylamide gel reiterated the specific 
interaction between immunogen and induced antibodies. 
Direct binding and inhibition ELISA experiments performed on serum 
samples of systemic lupus erythematosus and rheumatoid arthritis patients revealed 
that autoantibodies in the sera of these patients were recognizing peroxynitrite-
modified H2A better than native H2A or native DNA. Normal human sera showed 
negligible binding with either antigen. 
In conclusion, histones modified by laboratory synthesized peroxynitrite 
showed gross structural changes as revealed by physico-chemical results. 
Peroxynitrite-induced nitration and oxidation appears to have generated highly 
immunogenic epitopes on H2A histone. Experimentally produced antibodies 
against peroxynitrite-modified H2A were polyspecific because they showed 
specificity for the immunogen as well as cross-reaction with nitrated epitopes of 
other proteins. The preferential binding of peroxynitrite-modified histones by 
autoantibodies derived fi"om systemic lupus erythematosus and rheumatoid arthritis 
sera points out the role of oxidatively modified and nitrated proteins in the 
initiation/progression of systemic lupus erythematosus and rheumatoid arthritis. 
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Nucleosomes are the fundamental repeating units of eukaryotic chromatin. 
They package DNA into chromosomes inside the cell nucleus and control gene 
expression. Nucleosomes are made up of DNA and four pairs of histone proteins 
and resemble "beads on a string of DNA" when observed under electron 
microscope. H2A, H2B, H3 and H4 histones are part of the nucleosome while HI 
histone is associated with linker DNA that joins two nucleosome particles. 
General information on histones 
Histones are the chief proteins of chromatin and were discovered in the 
year 1884 by Albrecht Kossel. It has large proportion of positively charged amino 
acids, mainly arginine and lysine (9-30%). Core histones are highly conserved 
proteins and perform important role in the biology of the nucleus. Linker histone is 
less conserved than the core histones. 
Characteristics of histones 
Histones derived from calf thymus are acid soluble, positively charged, 
small molecular weight proteins (11-23 kDa) found in association with DNA in 
chromatin of most eukaryotes. They lack tryptophan and with the exception of the 
arginine rich H3, they also lack cysteine or cystine. In higher animals and in many 
lower eukaryotes, there are five main types of histones. Two of them contain 
excess of arginine (H3 and H4) and the remaining three histones contain more 
lysine than arginine and are known as lysine rich histone fi-actions (HI, H2A and 
H2B). In some specialized cells, such as nucleated eukaryotes in birds & 
spermatozoa of various animals, additional histone fractions have been found 
which differ in amino acid composition from the five main histone species 
(Hnilica et al, 1972; Delange and Smith, 1971; Stellwagen and Cole, 1969; Wigle 
and Dixon, 1971). 
Histones act as spools around which DNA is wrapped and they play critical 
role in gene regulation. This enables the compaction which is necessary to fit the 
large genomes of eukaryotes inside cell nuclei. The compacted molecule is 50,000 
times shorter than an unpacked molecule. Two each of the H2A, H2B, H3 and H4 
assemble to form one octameric nucleosome core particle by wrapping 146 base 
pairs of DNA around the protein spool. The linker histone (HI) binds the 
nucleosome and thus locking the DNA into place and allowing the formation of 
higher order structure. This involves the wrapping of DNA around nucleosomes 
with approximately 50 base pairs of DNA spaced between each nucleosome. 
Fraction nomenclature of the five histones in calf thymus is as follows; 
Histone type 
Lysine rich 
Slightly Lysine rich 
Slightly Lysine rich 
Arginine rich 
Arginine rich 
Bradbury 
nomenclature 
HI 
H2A 
H2B 
H3 
H4 
Johns nomenclature 
KAPorFlorl 
Lak or ALK or F2a2 or 
Ilbl 
KAS or KSA or F2b or 
IIb2 
ARE or ARK or F3 or III 
GRKor F2al or IV 
Molecular 
weight (kDa) 
21.50 
14.00 
13.77 
15.32 
11.28 
Source: Elgin and Weintraub, 1975 
Structure of nucleosome core is consist of two H2A-H2B dimers and two 
H3-H4 dimers. The 'core' histones (H2A, H2B, H3 and H4) are relatively similar in 
structure and are highly conserved. They also share the feature of long 'tails' on one 
end of the amino acid structure—this being the location of post-transcriptional 
modification. In all, histones make five types of interactions with DNA; 
i. Helix-dipoles from alpha-helices in H2B, H3 and H4 causes a net positive 
charge to accumulate at the point of interaction with negatively charged 
phosphate groups on DNA. 
ii. Hydrogen bonds between the DNA backbone and the amino group on the 
main chain of histone proteins. 
Non-polar interactions between the histone and deoxyribose sugars on 
DNA. 
Salt links and hydrogen bonds between side chains of basic amino acids 
(especially lysine emd arginine) and phosphate oxygen on DNA. 
Non-specific minor groove insertions of the H3 and H2B N-terminal tails 
into two minor grooves each on the DNA molecule. 
The highly basic natures of histones, aside from facilitating DNA-histone 
interactions, contribute to the water solubility of histones. Histones are subject to 
post-translational modification by enzymes primarily on their N-terminal tails. 
HI 
IV 
V. 
Such modifications include methylation, citnillination, acetylation, 
phosphorylation, ubiquitination and ADP-ribosylation. This affects their function 
of gene regulation. Post-translational modifications of histones alter their 
interaction with DNA and other nuclear proteins. 
Immunogenicity of histones 
Antibodies directed against defined regions of histone represent one of the 
most specific probes for studying the surface topography of nucleosome and 
chromatin and for monitoring post-translational modifications. In recent past, about 
two dozen antigenic determinants/epitopes of the four core histones have been 
identified. Most of these epitopes, known as continuous epitopes, correspond to 
linear stretches of 6-20 amino acid residues. It is noteworthy that all terminal 
regions of the four histones, except carboxy terminal residues of H4, correspond to 
continuous epitopes. Antibodies directed against the epitopes can be used to 
determine which regions of histone molecules are exposed at the surface of 
nucleosome and are useful probes for analyzing chromatin structure and function. 
Size of macromolecules play important role in its immunogenecity. The 
best immunogens tend to have a molecular mass approaching 10 kDa. Generally, 
substances with a molecular mass of less than 5-10 kDa are poor immunogens. 
Furthermore, size alone is not sufficient for immunogenicity, other properties are 
also needed. All four levels of protein organization—^primary, secondary, tertiary 
and quaternary contribute to the structural complexity of a protein and hence affect 
its immunogenicity (Goldsby et ai, 1999). 
Natiye core histones are poor immunogens. Their weak immunogenecity 
has been ascribed to highly conserved sequences and presence of few aromatic 
amino acid residues (Stoller, 1978; Bustin, 1979). Several laboratories have 
successfully prepared antibodies to nucleosome (Mura et al, 1980), but reports are 
lacking on production of antibodies to native core histones. However, animals 
immunized with core histones complexed with RNA or DNA induced good 
antibody response in experimental animals (Stoller and Ward, 1970). Similarly, 
triacetylated histones complexed with RNA have been reported to be immunogenic 
(Muller et al, 1991). Use of anti-histone antibodies as a probe has allowed 
detection of many details on the surface of the chromatin subunits 
(MuUer et al, 1982a; Muller et al, 1982b). Anti-histone antibodies as 
immunochemical reagents have also been useful in the elucidation of the role of 
histone post-translational modification in transcription and replication 
(Hebbes et al, 1988; Turner, 1991; Perry et al, 1993). 
Reactive nitrogen species 
Free radicals are reactive molecules with impaired electrons. They 
represent an important arm of host defense against a variety of pathogens 
(Zahrt and Deretic, 2002). Reactive nitrogen intermediates (as well as oxygen) are 
directly toxic to invading pathogens. These reactive species also activate redox-
sensitive signaling pathways, such as nuclear factor-kappa B (NF-KB) and activator 
protein-1 (AP-1), that in turn regulates the transcription of proinflammatory 
proteins such as cytokines (Rahman et al, 2006). During inflammation, 
overproduction of fi-ee radicals may lead to a break in immune tolerance, increased 
tissue damage and altered enzyme function. Reactive oxygen and nitrogen 
intermediates (RONI) play an important role in cellular signaling processes when 
produced at low levels. At higher levels, these molecules can cause direct toxicity 
to cells and induce modifications in lipids, amino acids and DNA (Oates and 
Gilkeson, 2006). However, to minimize damage by RONI, both enzymatic and 
non-enzymatic antioxidant defense plays important role. 
(i) Nitric oxide 
Nitric oxide (NO*) is probably the most relevant free radicals having broad 
spectrum of physiological and pathophysiological function. They are readily 
converted by enzymes or nonenzymic chemical reactions into reactive non-radical 
species, which can in turn give rise to new radicals. Radical and non-radical 
reactive nitrogen species include NO*, nitrogen dioxide (NO2), nitrous acid 
(HNO2), nitrosyl cation (NO*), nitrosyl anion (N0~), dinitrogen tetroxide (N2O4), 
dinitrogen trioxide (N2O3), peroxynitrite (0N00~), peroxynitrous acid (ONOOH), 
alky! peroxynitrites and nitronium cation (NO2 ). 
Nitric oxide is produced from L-arginine by the enzyme nitric oxide 
synthase (NOS). There are three isoforms of NOS: neuronal NOS (nNOS or 
NOS-I) originally identified in brain, inducible NOS (iNOS or NOS-II) originally 
identified in macrophages, and endothelial NOS (eNOS or NOS-III) originally 
identified in endothelial cells (Ghafourifar et al, 2001). iNOS is expressed in 
macrophages, endothelial cells, fibroblasts, vascular smooth muscle cells and 
cardiac myocytes in response to inflammatory cytokines, The expression of iNOS 
is regulated both at the level of transcription and iNOS mRNA stability. Catalytic 
activity of iNOS is regulated by the availability of the substrate, L-arginine, and of 
the cofactors, NADPH and tetrahydrobiopterin. Induction of iNOS expression is 
complemented by co-induction of cationic amino acid transporter proteins 
(increase in the intracellular L-arginine level) and GTP cyclohydrolase (key 
enzyme of tetrahydrobiopterin synthesis). Increased NO* production via induction 
of iNOS has been suggested as a major mechanism by which cytokines mediate 
inflammatory responses and development of autoimmune diseases. (Turko and 
Murad, 2002). 
(ii) Peroxvnitrite 
Peroxynitrite is powerful oxidant and nitrating agent. It is formed by 
reaction of superoxide (a reactive oxygen species) and nitric oxide (a reactive 
nitrogen species). Peroxynitrite has been reported in endothelial cells 
(Palmer et al, 1988), macrophages (Ischiropoulos et al, 1992a), neuronal cells 
(Lafon-Cazal et al, 1993), neutrophils (Carreras et al, 1994) and smooth muscle 
cells (Schulz era/., 1991) etc. 
The decay of peroxynitrite is strongly influenced by temperature and 
transition metal ions which catalyze isomerisation of peroxynitrite. In aqueous 
alkaline solutions, peroxynitrite anion is stable for weeks if kept frozen in dark 
(Gmelin, 1996). The peroxynitrite anion shows maximum absorption at 302 nm 
with an extinction coefficient of 1670 M~'cm"' (Hughes and Nicklin, 1968). 
Contrary to above, peroxynitrous acid gives maximum absorption at 345 nm with 
an extinction coefficient of 80 MT'cm"'; shoulder at 250 nm with an extinction 
coefficient of 600 M~'cm~' has also been observed. 
Peroxynitrite has a biological half life of 10-20 milliseconds and possess 
the ability to destroy critical cellular components (Beckman et al, 1990; 
Denicola et al, 1998). It can oxidize thiols (Radi et al, 1991b) and/or nitrate DNA 
(Inoue and Kawanishi, 1995; Salgo et al, 1995), proteins (Ischiropoulos and 
Al-Mehdi, 1995; Grune et al, 2001) and lipids (Radi et al, 1991a). At 
physiological pH, about 20% of peroxynitrite is protonated to peroxynitrous acid 
(HOONO) which has a pka of 6.8. This fraction of peroxynitrous acid play 
significant role in the biological activity. For example, one- and two-electron 
oxidations can be performed by peroxynitrite. Different mechanisms of reactivity 
of peroxynitrite have been proposed (Denicola et al, 1996) and the same has been 
shown in scheme I. As depicted in reaction I peroxynitrite anion (0N00~) may 
directly react with sulfhydryls (RSH) to yield corresponding disulfide (RSSR). 
Peroxynitrite anion may also nitrate aromatic rings (R-Ar) to yield nitro-
derivatives (reaction II). When protonated to peroxynitrous acid (ONOOH), it can 
react with biomolecules (SI) (reaction III). It can also undergo a rate-limiting 
transition to vibrationally activated intermediate (ONOOH*). The activated 
intermediate can isomerize to nitric acid (reaction V) or oxidize a target molecule 
(S2; such as benzoate or DMSO) with a reactivity similar to that of hydroxyl 
radical (reaction IV) 
ONO2COJ HC03~ 
.1 1 
CO7 
•NO + o r *- 0N00~ ^ ^ ' ONOOH . ONOOH-'—• NO7 + H* 
R-SH 
R-S-S-R 
Scheme 1. Reactions of peroxynitrite 
Furthermore, the peroxynitrite anion may also react with carbon dioxide 
(physiological concentration of the latter is about 1 mM in blood plasma) with a 
rate constant of 3 x 10'' NT's"' at 25°C (Lymar and Hurst, 1995). This reaction 
produces l-carboxylato-2-nitrosodioxidane (0N00C02~) which is mainly 
responsible for toxicity of peroxynitrite. In the absence of other reactants, 
0N00C02~ undergoes hemolysis and forms nitrogen dioxide and trioxocarbonate 
radicals with a yield of 4-30% (Coddington et al, 1999; Bonini et al, 1999; 
Meli et al, 2002; Lymar and Hurst, 1998) which isomerises to nitrate and carbon 
dioxide. 
Since its published discovery in the year 1987, peroxynitrite has received 
overwhelming attention of biomedical researchers because of its involvement in the 
regulation of blood pressure and activities in brain, lungs, kidneys, stomach, gut etc. 
Numerous studies have demonstrated that peroxynitrite toxicity is due to its 
ability (a) to oxidize thiols and thiol containing proteins and membrane lipids 
(Radi et al, 1991a; Radi etal, 1991b) and (b) to nitrate phenols including free and 
protein bound tyrosines. Proteins react with peroxynitrite to form a stable yellow 
protein-bound adduct identified as nitrotyrosine (Ischiropoulos et al, 1992b). 
Because of its oxidant nature, peroxynitrite can directly react with electron-
rich groups; such as sulfhydryls (Radi et al, 1991b), iron-sulfur centers 
(Castro et al, 1994), zinc-thiolates (Crow et al, 1995) and active site sulfhydryl in 
tyrosine phosphatases (Takakura et al, 1999). Curiously, the reaction rate constant 
for these second-order reactions varies from 10" to 10° M" s"'. Although 
peroxynitrite is a strong oxidant, but its anion (0N00"~) reacts directly with 
molecules carrying partial positive charges. In addition to nitrotyrosines, 
peroxynitrite can also produce novel products such as nitrotryptophan and nitrated 
lipids that may emerge as important biological markers in vivo. 
Peroxynitrite as an oxidant and nitrating agent 
Oxidation reactions of peroxynitrite include DNA damage, leading to base 
modification (Douki et al, 1996) and mutations as well as single- and double-
strand breaks (Salgo et al, 1995; Szaboe and Ohshima, 1997). Peroxynitrite also 
causes one- or two-electron oxidation of sulfhydryls (Quijanoet et al, 1997) 
leading to thiyl radical formation, radical chain reactions and depletion of thiol 
pools. Nitration reactions are predominantly nitration of phenols, such as nitration 
of tyrosine residues in proteins. Protein tyrosine nitration by peroxynitrite may 
interfere with phosphorylation/dephosphorylation signaling pathways (Kong 
et al, 1996; Li et al, 1998). Because of its cytotoxic action on bacteria (Zhu 
et al, 1992) or other invading pathogens, the peroxynitrite may prove useful. 
Inflammatory cells (macrophages and neutrophils) produce large amount of both 
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nitric oxide and superoxide which rapidly combines to form peroxynitrite 
(Huie and Padmaja, 1993; Kissner et al. 1997; Ischiropoulos et al, 1992a). 
However, excessive production of peroxynitrite can damage normal tissues. 
Indeed, the formation of protein 3-nitrotyrosine in vivo has been shown in a 
number of inflammatory conditions in humans and experimental animals 
(Ischiropoulos, 1998). 
Scavengers of peroxynitrite 
Peroxynitrite and peroxynitrite-derived radicals may be neutralized by 
several molecules. In animal models of inflammation and reperfusion injury both 
uric acid and ascorbic acid have shovm beneficial effects (Szabo et al, 2007; 
Yeo et al, 2008). Scavenger action of these acids is more pronounced on 
peroxynitrite derived radicals. Simple thiol-based antioxidants, such as 
mercaptoalkylguanidines, N-acetylcysteine, cystein and dihydrolipoic acid have 
shovm reduction in peroxynitrite-mediated toxicity and reduce 3-nitrotyrosine 
immunoreactivity in various pathophysiological conditions (Szabo et al., 2007). 
Ebselen and several unsaturated oils have exerted protective effects in numerous 
models of inflammation and reperfusion injury (Sugiura et al. 1999; Daiber 
et al., 2000; Noiri et al., 2001). Some of these actions are likely to be associated 
with the ability of the compound to neutralize peroxynitrite. Indeed, the selenium-
containing glutathione peroxidase and other enzymes such as catalase, superoxide 
dismutase have been shown to readily reduce peroxynitrite to nitrite in vitro, but 
their protective role in in vivo has not been confirmed (Afonso et al, 2007). 
Several marketed antioxidants (such as dithiothreitol and DMSO) have been 
demonstrate to scavange peroxynitrite derived secondary radicals. Whether the 
antioxidant effects of these compounds will contribute to their therapeutic actions 
remain to be seen. Desferrioxamine has been typically used in vivo as an iron 
chelator and therefore an inhibitor of iron dependent generation of hydroxy! 
radicals. However, desferrioxamine has also inhibited peroxynitrite-dependent 
oxidation and nitration by reacting with the C03~* and NO2* radicals (Bartesaghi 
et al, 2004). Recent studies demonstrate that tyrosine-containing peptides can also 
act as scavengers of peroxynitrite derived radicals at the cellular level and may 
neutralize the cytotoxic effects of both exogenous and endogenous peroxynitrite, 
inhibiting its pro-apoptotic effect on neurons (Ye et al, 2007). 
Peroxynitrite-induced cytotoxicity 
Under physiological conditions, production of peroxynitrite remains low 
and oxidative damage is neutralized by endogenous antioxidant defenses (Radi 
et al, 2002a; Radi et al, 2002b; Trujillo et al, 2008). Even modest increase in the 
simultaneous production of superoxide and nitric oxide will greatly stimulate 
peroxynitrite formation, a 10-fold increase in superoxide and nitric oxide will 
causes 100-fold increase in peroxynitrite formation. The generation of a moderate 
flux of peroxynitrite over a long period of time will result in substantial oxidation 
and potential destruction of host cellular constituents, leading to the dysfunction of 
critical cellular processes, disruption of cell signaling pathways and the induction 
of cell death through both apoptosis and necrosis (Virag et al, 2003). Hence, the 
production of peroxynitrite can be instrumental in the development of many 
pathological processes in vivo. 
Although not a free radical, peroxynitrite is much more reactive than either 
nitric oxide or superoxide (Beckman, 1990; Beckman and Koppenol, 1996). The 
half-life of peroxynitrite is short (10-20 milli seconds) but sufficient to cross 
biological membranes, diffuse one to two cell diameters (Denicola et al, 1998) and 
allow significant interactions with most critical biomolecules (Pryor and 
Squadrito, 1995). Kinetic studies indicated that peroxynitrite oxidizes target 
molecules through two distinct mechanisms. First, peroxynitrite and its protonated 
form (peroxynitrous acid; ONOOH) can cause direct oxidative modifications 
through one- or two-electron oxidation processes (Beckman et al, 1996). Second, 
peroxynitrite can yield hydroxyl radical and nitrogen dioxide radical (NO2) during 
the homolytic decomposition of peroxynitrous acid. However, the formation of 
hydroxyl radical by this mechanism probably plays only a minor role in in vivo 
(Radi, 1998) because of the particularly rapid reaction of peroxynitrite with carbon 
dioxide. 
Peroxynitrite in apoptosis and necrosis 
Mitochondria are involved in energy production, calcium homeostasis, 
control of various biosynthetic pathways etc. Disruptions of mitochondrial 
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functions have been implicated in diabetes, atherosclerosis, ischemic heart diseases, 
stroke, aging, neurodegenerative diseases etc. The mitochondrial toxicity of 
peroxynitrite results both from direct oxidative reactions as well as from free 
radical-mediated damage (Radi et al, 2002a; Radi et al, 2002b). The damaging 
potential of peroxynitrite is due to direct oxidation as well as radical-mediated 
nitration reactions. These properties allow peroxynitrite to significantly alter 
fimction of a number of proteins, to degrade membrane structure by peroxidizing 
lipids, to turn off crucial metabolic fimctions within mitochondria and to inflict 
serious damage to nucleic acids. Once the level of cellular damage inflicted by 
peroxynitrite supercedes any possibility of repair, the cell eventually dies via one of 
the two main pathways of cell demise, necrosis or apoptosis. Necrosis is associated 
with loss of cellular ATP, leading to membrane disruption, release of noxious 
cellular debris, and the development of secondary inflammation. In contrast, 
apoptosis occurs in a well-choreographed sequence of morphological events 
characterized by nuclear and cytoplasmic condensation with blebbing of the plasma 
membrane. Apoptosis is orchestrated by the proteolytic activation of cysteine 
proteases known as caspases, that requires preserved ATP levels to proceed 
properly and which may be triggered either by the activation of death receptors 
(extrinsic pathway) or by the permeabilization of the outer membrane of 
mitochondria (intrinsic pathway) (Bouchier-Hayes et al, 2005; Newmeyer and 
Ferguson-Miller, 2003). Peroxynitrite has been associated with apoptosis in 
HLA-60 cells (Lin et al. 1995), PC 12 cells (Estevez et al, 1995), fibroblasts 
(Raghuram et al, 1999), SN 4741 dopaminergic neurons (Shacka et al, 2006), 
SH-SY5Y neuroblastoma cells (Saeki et al, 2002), primary neurons (Bonfoco 
et al, 1995; Estevez et al, 1998; Kanski et al, 2005; Kanski et al, 2005), 
astrocytes (Zhu et al, 2006) and oligodendrocytes (Zhang et al, 2006) endothelial 
cells (Dickhout et al, 2005; Walford et al, 2004), beta islet cells (Delaney 
et al, 1996; Suarez-Pinzon et al, 1997), neutrophils (Fortenberry et al, 1998; 
Taylor et al, 2004), chondrocytes (Whiteman et al, 2004), cardiomyocytes 
(Arstall et al, 1999; Levrand et al, 2006) and renal tubular cells (Allen 
et al, 2003). Several mechanisms have been proposed to explain the activation of 
the apoptotic program by peroxynitrite. However, a common pathway involving 
11 
the mitochondria and permeabilization of their outer membrane is emerging as a 
key feature of peroxynitrite-mediated apoptosis which is a prominent feature of 
peroxynitrite-mediated cell death. 
Whereas apoptosis is a typical consequence of low to moderate 
concentrations of peroxynitrite, exposure of cells to higher concentrations of the 
oxidant has been associated with necrosis (Bonfoco et al., 1995; Virag 
et al, 2003). Peroxynitrite-dependent cell necrosis is not a purely passive 
phenomenon, but instead is mediated by a complex process involving DNA 
damage and activation of the DNA repair enzyme poly (ADP-ribose) polymerase 
(PARP-1) ( Szabo et al, 1996). Poly (ADP-ribose) polymerase is a member of the 
PARP enzyme family consisting of PARP-1 and many additional poly (ADP-
ribosylating) enzymes. An important function of PARP-1 is to allow DNA repair 
and cell recovery in conditions associated with a low degree of DNA damage as a 
result, the loss of NAD"*^  leads to a marked decrease in the cellular pools of ATP, 
resulting in cellular dysfunction and cell death via the necrotic pathway (Ha and 
Snyder, 1999; Liaudet and Oddo, 2003). As such, PARP cleavage has been 
proposed to function as a molecular switch between apoptotic and necrotic modes 
of cell death (Boulares et al, 1999; Levrand et al, 2006; Los et al, 2002). 
Reaction of peroxynitrite with proteins 
(i) Reactions with proteins containing transition metal: The direct reaction of 
peroxynitrite with transition metal centers is among the fastest known for 
peroxynitrite (Alvarez and Radi, 2003). Peroxynitrite thus can modify proteins 
containing a heme prosthetic group; such as hemoglobin (Boccini and 
Herold, 2004), myoglobin (Herold et al, 2003), or cytochrome C (Thomson 
et al, 1995) by oxidizing ferrous heme into the corresponding ferric form. 
Similarly, peroxynitrite can inactivate inducible nitric oxide synthase (iNOS) by 
oxidative modification of its heme group (Huhmer et al, 1997), a reaction which 
might serve as a feedback negative regulation of peroxynitrite generation under 
inflammatory conditions. Peroxynitrite can also react with iron-sulfur clusters 
thereby inactivating mitochondrial aconitase (Castro et al, 1994) and 
phoshogluconate dehydratase (Keyer and Imlay, 1997) involved in critical 
metabolic processes. Similarly, reaction of peroxynitrite withZn^* sulfur motifs of 
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endothelial nitric oxide synthase (eNOS) (Zou et al, 2004) and alcohol 
dehydrogenase (Crow et al, 1995) causes inactivation of these enzymes. 
(ii) Reactions with cysteine: Reaction of peroxynitrite with various amino acids 
alters protein structure and function. Upon reaction with cysteine, peroxinitrite 
causes thiol oxidation (Radi et al, 1991b). Oxidation of critical cysteine residues 
inactivates many enzymes of cellular energetic processes; some examples are; 
glyceraldehyde-3-phosphate dehydrogenase (Buchczyk et al, 2003; Souza and 
Radi, 1998), creatine kinase (Konorev et al, 1998), complex I (NADH 
dehydrogenase), complex II (succinate dehydrogenase), complex III (cytochrome c 
reductase) as well as complex V (ATP synthase) of the mitochondrial respiratory 
chain (Radi et al, 1994, Radi et al, 2002a; Radi et al, 2002b). Furthermore, these 
enzymes are also inactivated by nitration of tyrosine residues. The susceptibility of 
cells to peroxynitrite toxicity largely depends on the amount of intracellular 
glutathione. Depletion of glutathione enhances peroxynitrite toxicity and tissue 
injury during circulatory shock (Cuzzocrea et al, 1998; Cuzzocrea et al, 1999). A 
correlation between glutathione depletion and enhanced peroxynitrite toxicity has 
also been respected in some neurodegenerative diseases such as Parkinson's disease 
and amyotrophic lateral sclerosis (Marshall et al, 1999; Vargas et al, 2006). 
(Hi) Reaction with tryptophan, methionine and histidine: Peroxynitrite mediated 
oxidation of methionine generates methionine sulfoxide and to a lesser extent 
ethylene and dimethyldisulfide (Alvarez and Radi, 2003). Methionine oxidation 
can also inhibit alpha-1-antiproteinase which then loses ability to inactivate 
proteases most notably elastase (Whiteman et al, 1996). Peroxynitrite can also 
oxidize tryptophan (Alvarez and Radi, 2003) to A'^ -formylkynurenine, oxindole, 
hydropyrroloindole and nitrotryptophan, but relevance of these products is yet to be 
understood (Alvarez and Radi, 2003; Yamakura and Ikeda, 2006). Peroxynitrite 
modifies histidine through a radical mechanism, forming a histidinyl radical, a 
mechanism involved in the inactivation of Cu-Zn superoxide dismutase by 
peroxynitrite (Alvarez et al, 2004; Yamakura and Ikeda, 2006; Yamakura 
et al, 2005). 
(iv) Reaction with tyrosine: Tyrosine nitration by peroxynitrite is a covalent 
modification that results in addition of a nitro (-NO2) group adjacent to the 
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hydroxyl group on the aromatic ring of tyrosine residues (Gow et al, 2004). It may 
cause generation of new epitopes, changes in enzymes catalytic activity, aUered 
cytoskeletal organization and impaired cell signal transduction (Virag and 
Szabo, 2000). Tyrosine nitration occurs through radical mechanism in which a 
hydrogen atom is first abstracted from tyrosine to form a tyrosyl radical that 
quickly combines with nitrogen dioxide radical to produce 3-nitrotyrosine. 
Nitrotyrosine performs a secondary reaction where it combines with another 
tyrosyl radical to form dityrosine (Beckman, 1996; Beckman et al, 1996; 
Ischiropoulos, 2003; Radi, 2004). Although the nitrogen dioxide radicals involved 
in the reaction may come from homolysis of peroxynitrite to form hydroxyl and 
nitrogen dioxide radicals (like HO and NO2'), they most likely come from reaction 
of peroxynitrite with CO2 producing C03~« and NO2* radicals (Alvarez and Radi, 
2003; Radi, 2004; Turko and Murad, 2002). A second mechanism of tyrosine 
nitration relies on the generation of the nitrogen dioxide radical from various heme-
peroxidases (mainly myeloperoxidase and eosinophil peroxidase) in presence of 
hydrogen peroxide (Gaut et al, 2001; Van der Vliet et al, 1997; Wu et al, 1999). 
This may serve as a recycling mechanism to reuse products formed from 
superoxide and NO*. Therefore, nitrotyrosine formation technically must be 
considered a marker of "nitrosative" stress. 
The advent of proteomic analyses has confirmed that nitration is a highly 
selective process, limited to specific tyrosine residues on a surprisingly small 
number of proteins (Aulak et al, 2001; Gow et al, 2004; Kanski et al, 2005a; 
Kanski et al, 2005b). Nitration on specific tyrosine residues is promoted by the 
exposure of the aromatic ring to the surface of the protein, the location of the 
tyrosine on a loop structure, its association with a neighboring negative charge and 
absence of proximal cysteines (Souza et al, 1999). Tyrosine nitration may also be 
favored in hydrophobic environment considering that peroxynitrous acid can 
readily pass through lipid membranes (Bartesaghi et al, 2006; Turko and 
Murad, 2002). 
Protein oxidation 
The reaction of intracellular peroxynitrite with cellular structures will lead 
to a multitude of damages including protein modification. Peroxynitrite-induced 
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modification of proteins includes oxidation (of methionine, cysteine, tryptophane 
or tyrosine residues) and nitration (of tyrosine and/or tryptophane residues). 
However, the product of protein-peroxynitrite interaction investigated most often 
is 3-nitrotyrosine (Beckman and Koppenol, 1996; Kong et al, 1996; Ischiropoulos 
et al, 1992b). Enzymes containing a redox active transition metal center are the 
prime targets (Beckman and Koppenol, 1996). Reactions of peroxynitrite are 
affected by the local pH and the microenvironment with hydrophobic membrane 
compartments favoring nitration and aqueous environments favoring oxidation. 
Moreover, carbon dioxide reacts with peroxynitrite resulting in the formation of 
nitroso-peroxocarbonates (Radi et al, 2001). The ubiquitous presence of CO2 at 
high concentration may favor this reaction route. As nitroso-peroxo carbonates 
divert peroxynitrite induced protein modifications toward nitration, CO2 is now 
considered as key determinant of peroxynitrite chemistry. Peroxynitrite can 
directly oxidize prosthetic groups of a protein, e.g. hemoglobin, or directly react 
with the peptide chain leading to conformational and functional changes with 
severe biological consequences. Enzymes with critical cysteine residues can be 
inactivated by peroxynitrite (Takakura et al, 1999). Finally, oxidation of a critical 
cysteine residue was found to activate matrix metalloproteinases where the 
cysteine residue is in the auto-inhibitory domain of the proenzyme (Okamoto 
et al, 1997). In case of peroxiredoxine (thiol-dependent peroxidases) oxidation of 
cysteine residues to disulfide (via sulfenic acid) is part of the catalytic cycle (Bryk 
et al, 2000). Protease inhibitory properties of al-antiproteinase are lost after 
peroxynitrite-mediated oxidation of its critical methionine residues to methionine 
sulfoxide (Moreno and Pryor, 1992). The oxidation of methionine is readily 
reversed by methionine sulfoxide reductase at the expenses of thioredoxin. 
Protein carbonyl 
Generation of free radicals and oxidants is common during normal 
metabolism (Tobias et al, 2007). It may also be a sign of normal aging or a 
hallmark of pathologic processes (Klaunig and Kamendulis, 2004; Emerit 
et al, 2004; Bailey, 2003; Fubini and Hubbard, 2003). It is true both for reactive 
oxygen- and reactive nitrogen species. The peroxynitrite anion (0N00~) is a 
highly reactive molecule (Gow et al, 1996; Stadtman, 2001; Castegna et al, 2003; 
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Souza et al, 1999) and has low diffusion distance in biological tissue 
(Ischiropoulos and Al-Mehdi, 1995). The most prominent analyzing marker for 
protein oxidation is carbonyl contents of proteins (Berlett and Stadman, 1997; 
Chevion et al, 2000; Shacter, 2000; Beal, 2002). Carbonyl appears (C=0) as a 
consequence of oxidative modification of the side chains of lysine, proline, 
arginine and threonine (Berlett et al, 1998). These moieties are chemically stable. 
Protein carbonyl derivatives can also be generated through oxidative cleavage of 
proteins by either the a-oxidation pathway or by oxidation of glutamyl side chains, 
leading to formation of a peptide in which the N-terminal amino acid is blocked by 
an a-ketoacyl derivative (Berlett and Stadman, 1997). Determination of protein 
C=0 groups as biomarker of oxidative stress has some advantages over 
measurement of other oxidation products because of stability of former. 
Accumulation of protein carbonyls has been observed in Alzheimer's disease, 
diabetes (Ceriello, 2008), inflammatory bowel disease, systemic lupus 
erythematosus, rheumatoid diseases, sepsis, chronic renal failure, respiratory 
distress syndrome (Dalle-Dome et al, 2003; Ghafourifar et al, 2008), cancer 
(Yilmaz et al, 2003) etc. 
Reaction of of peroxynitrite with lipids 
A major aspect of peroxynitrite-dependent cytotoxicity relies on its ability 
to trigger lipid peroxidation in membranes, liposomes and lipoproteins by 
abstracting a hydrogen atom from polyunsatturated fatty acids (Radi et al, 1991a). 
Resulting products include lipid hydroperoxyradicals, conjugated dienes, and 
aldehydes (Denicola and Radi, 2005). Such radicals in turn attack neighboring 
polyunsatturated fatty acids, generating additional radicals which propagate free 
radical reactions and ultimately degeneration of membrane lipids (Hogg and 
Kalyanaraman, 1999; Radi et al, 1991a) causing changes in membrane 
permeability and fluidity (Smith et al, 1999). Peroxynitrite may play a critical role 
in inflammatory diseases of the nervous system by initiating peroxidation of 
myelin lipids leading to demyelination (Shi et al, 1999; Smith et al, 1999; Van 
der Veen and Roberts, 1999). It can also act as a potent oxidizing agent towards 
low-density lipoprotein (LDL) (Leeuwenburgh et al, 1997; Trostchansky 
et al, 2003). Peroxynitrite-modified LDL binds to scavenger receptors with high 
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affinity leading to the accumulation of oxidized cholesteryl esters and foam cells 
which are key molecules of atherogenesis (Graham et al, 1993; Guy et al, 2001; 
Hogg et al, 1993). Finally, the interaction of peroxynitrite with membrane lipids 
may lead to various nitrated lipids which can act as potential biological mediators 
of signal transduction under physiological and pathological conditions (Baker 
e/flf/.. 2004). 
Reactions of peroxynitrite with DNA 
Peroxynitrite can damage DNA by introducing oxidative modifications in 
both nucleobases and sugar-phosphate backbone. Among the four nucleobases, 
guanine is the most reactive with peroxynitrite due to its low reduction potential 
(Yu et al, 2005). The major product of guanine oxidation is 8-oxoguanine, which 
upon further reaction with peroxynitrite yields cyanuric acid and oxazolone (Niles 
et al, 2006). Ultimately, guanine oxidation by peroxynitrite results in guanine 
fragmentation, a critical step towards mutagenesis and carcinogenesis (Bumey et 
al, 1999; Niles et al, 2006). Peroxynitrite can also nitrate guanine, yielding 8-
nitro-guanine, which leads to formation of abasic sites and that can be cleaved in 
vivo by endonucleases to give DNA single-strand breaks (Bumey et al, 1999; 
Niles et al, 2006). Peroxynitrite may also attack the sugar-phosphate backbone by 
abstracting a hydrogen atom from the deoxyribose moiety, resulting in opening of 
the sugar ring and generation of DNA strand breaks (Bumey et al, 1999; Niles 
et al, 2006). The formation of DNA single-strand breaks represent a critical aspect 
of peroxynitrite-mediated cytotoxicity, since they represent the obligatory trigger 
for the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), a 
pathway ultimately related to the induction of cell death and tissue inflammation 
(Szabo et al, 1996; Pacher and Szabo, 2008). 
Peroxynitrite and human diseases 
The hypothesis that peroxynitrite generation beyond body's defense 
contributes to myocardial and vascular dysfunction during ischemia and 
reperfusion, myocarditis, chronic heart failure and other cardiovascular pathologies 
has been the focus of intensive investigations during the last decade. Peroxynitrite 
may contribute to vascular pathophysiology by various mechanisms including 
triggering apoptosis and/or PARP-dependent cell death in endothelium 
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(Dickhout et al, 2005; Mihm et al, 2000) and vascular smooth muscle cells 
(Li et al, 2003; Li et al, 2004b) by inducing up-regulation of adhesion molecules 
in endothelial cells, endothelial glycocalyx disruption, enhancing neutrophils 
adhesion (Pacher et al., 2007), inhibiting voltage-gated K* K(v) and Ca^^-activated 
K^  channels in coronary arterioles (Li et al, 2004a; Liu et al, 2002) and vascular 
prostacyclin synthase (Pacher et al, 2007). Furthermore, clinically relevant 
concentrations of 3-nitrotyrosine (present in various pathophysiological diseases) 
result in concentration-dependent impairment of acetylcholine-induced, 
endothelium-dependent vascular relaxation and may induce DNA damage in 
vascular endothelial cells (Mihm et al, 2000; Zou et al, 2002). 
There are four major mechanisms underlying the toxicity of peroxynitrite in 
shock. These include lipid peroxidation, depletion of antioxidant reserves 
(especially reduced GSH), oxidation/nitration of proteins (especially mitochondrial 
proteins) and finally, induction of DNA damage leading to the activation of poly 
(ADP-ribose) polymerase (Gonsette, 2008). In addition to direct cytotoxic effects 
of peroxynitrite such as peroxidation of lipids, proteins and DNA, peroxynitrite 
also occupies a critical position in a positive feedback loop of inflammatory injury, 
activating pro-inflammatory signaling and by triggering the recruitment of 
phagocytes within injured tissues, leading to further nitric oxide combine 
superoxide to form peroxynitrite, which will progressively amplify the initial 
inflammatory reactions. These observations point out that reduction of 
peroxynitrite or its precursors might have a considerable therapeutic impact in 
clinical circulatory shock. 
Autoimmunity 
It is a physiological inherent feature of the human immune system 
(Wardemann and Yurasov, 2003: Janeway et al, 2005) defined by the presence of 
auto-reactive lymphocytes and antibodies. Development of the disease by 
transferring the active component of the immune response to an appropriate 
recipient (usually an animal model, or in some instances matemo-fetal transfer of 
autoantibody) is the best proof that a disease is caused by autoimmunity. 
Autoimmune diseases can be organ specific (Hashimoto's thyroiditis, 
Thyrotoxicosis, Pernicious anaemia, Addison's disease. Insulin dependent diabetes 
18 
mellitus, etc) or non-organ specific (like Scleroderma, Sjogren's syndrome, 
Dermatomyositis, Systemic vasculitis. Systemic lupus erythematosus etc). 
Evidence for genetic influence predisposing to autoimmunity is provided 
by studies on families. Moreover, many autoimmune diseases are linked to the 
major histocompatibility complex, which control a number of aspects of the 
immune response including antigen presentation. With one or two exceptions, 
however, the genes controlling predisposition to autoimmunity are heterogeneous 
within individuals and even within specific diseases. Of the environmental factors, 
infections appear to be the loss of tolerance to self-antigens (Wucherpfennig, 
2001). Mechanisms whereby infections may cause autoimmunity include 
molecular mimicry; by the production of superantigens; via enhanced processing 
and presentation of autoantigens during an infection (epitope spreading); and by 
provoking bystander activation (Wucherpfermig, 2001). The potential ability of 
infectious agents to unlash the immune system to destructive attack by shifting it 
away from itself is known to include strategies of conftising the immune system by 
virtue of cross-reactivity or molecular mimicry (McClain and Heinlen, 2005) or by 
inducing polyclonal activation of B cells (Granholm and Cavalio, 1992) and 
possibly loss of fimctional suppressor T-cells (Janeway et al, 2005). 
Mechanism of production of autoantibodies against protein antigens 
What triggers autoantibody production is a pivotal question to be answered 
in understanding the onset of autoantibodies-induced autoimmune diseases. 
Generally, majority of endogenous antigens are non-immunogenic due to 
immunological tolerance at the T cell and/or B-cell level. It has been suggested 
that self-proteins are rendered immunogenic if they are chemically modified post-
translationally under various physiologic or pathologic conditions (Doyle and 
Mamula, 2001; Utz. and Anderson, 1998). In inflamed tissues or apoptotic cells, a 
variety of structurally modified proteins have been found (Doyle and 
Mamula, 2001; Piacentini and Colizzi, 1999; Ohmori and Kanayama, 2003). Such 
protein modifications may lead to the generation or unmasking of new antigenic 
epitopes that will serve to activate B-cells and/or T-cells, thereby impairing or 
bypassing immunological tolerance (Ohmori and Kanayama, 2005). The excluded 
B-cells are short-lived (1-2 days) and require stronger signals for activation than 
19 
non-auto-reactive B-cells, thereby decreasing the risk of autoimmune responses 
(Liu, 1997; Townsend et al, 1999). Strict clonal deletion for establishing 
immunological tolerance may result in the formation of "holes" in the lymphocyte 
repertoire. Individuals with such "holes" will be susceptible to the attack by 
pathogens that possess self-mimicking epitopes. Thus, the leakiness of the central 
tolerance may be important to overcome the "hole problem" in the B-cell 
repertoire (Townsend et al, 1999). If the auto reactive B-cells present in the 
periphery are activated, and recruited to the affinity maturation pathway, this may 
lead to generation of pathogenic autoantibodies (Kouskoff et al., 2000; 
Mease^  2008). 
Post-translational modification of self-proteins is a physiological 
mechanism of generating new antigenic epitopes and T-cell tolerance has been 
suggested to be broken or bypassed if new antigenic epitopes are created on self-
proteins (Ohmori and Kanayama, 2005). Moreover, the reactivation of silenced 
self-reactive B-cells is believed to be one of the critical mechanisms triggering 
autoantibody production. Post-translational modifications include, for instance, 
transglutamination, isomerization to isoaspartyl, deamidation, deimination 
(citruUination), glycosylation, oxidation, phosphorylation, transglutaminase-
mediated cross-linking, proteolytic cleavage by granzymes or caspases, oxidative 
fragmentation (Utz and Anderson, 1998; Amoura et al, 1999; Casciola-
Rosen et al, 1997) and nitration. Some proteins listed in Table 1 have been found 
to generate neo-epitopes upon post-translational modifications. 
Histochemical analysis of proteins from inflamed or infected tissues have 
revealed nitrotyrosine in their structure. Influenza virus-infected mice, alveolar 
macrophages and neutrophils were intensely stained with anti-nitrotyrosine 
antibodies (Akaike et al, 1996). Macrophages obtained from surgical resection of 
lung & colonic cancers also contain nitrotyrosine-immunopositive proteins in the 
cytoplasm (Brito et al, 1999). IgG antibody against nitrotyrosine may be formed in 
vivo under inflammatory conditions because nitrotyrosine-IgG complex have been 
reported in synovial fluids of rheumatoid arthritis patients (Uesugi et al, 2000). It 
has been suggested that nitrotyrosine may serve as a B-cell epitope because both 
polyclonal and monoclonal anti-nitrotyrosine antibodies have been prepared by 
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immunization with nitrotyrosine-bearing heterologous proteins (Ye et al. 1996). 
An interesting feature of nitrotyrosine is its structural similarity to a synthetic 
hapten called 4-hydroxy-3-nitrophenylacetyl (NP). Anti-dsDNA antibodies from 
lupus mice are generally polyreactive (Radic and Weigert, 1994; Eilat and 
Naparstek, 1999) and have been found to cross-react with NP-related haptens 
(Zoualie/a/., 1987). 
Table 1 
List of proteins which have given birth to new antigenic epitopes after 
post-translational modification reactions 
Modification 
reaction 
Substrate protein Reference 
Transglutamination 
Isoaspartylation 
Deamidation 
Deimination 
(citrullination) 
Glycosylation 
Oxidation 
Phosphorylation 
Tyrosine nitration 
Histone H2B, actin, myosin, Doyle and Mamula, 2001 
keratins 
snRNP Doyle and Mamula, 2001 
Wheat gliadin 
Myelin basic protein, fibrin 
Type II collagen 
LDL 
SoUid, 2000 
Cao etal., 1998 
Corthay e/a/., 1998 
Shoenfelde/a/., 2001 
Doyle and Mamula, 2001 Pre-mRNA splicing factors 
ap-crystallin 
Multiple proteins in inflamed Ischiropoulos, 1998 
tissues 
Autoimmune diseases 
Autoimmune diseases are those which result from immunologic reactions, 
humoral and/or cellular or a combination of both. These diseases may be classified 
in different ways; it may be organ/tissue specific such as Hashimoto's thyroiditis, 
Thyrotoxicosis, Pernicious anaemia, Addison's disease. Insulin dependent diabetes 
mellitus. Myasthenia gravis etc. (Bodil et al, 2008; Bizzaro, 2008) or non-organ 
specific (systemic) such as autoimmune haemolytic anaemia. Systemic lupus 
erythematosus. Idiopathic thrombocytopenia purpura. Autoimmune leucopenia, 
Chronic active hepatitis, Coeliac disease, Autoimmune enteropathy. Autoimmune 
polyendocrinopathy, Sjogren's syndrome, Dermatomyositis, Systemic vasculitis, 
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Anti-phospholipid syndrome etc. (Pittock et al, 2008). No single theory or 
mechanism can adequately explain all the features of autoimmune diseases. 
However, three models have been proposed for the induction of a productive 
autoimmune process. The first is the autoimmune response to a cross-reacting 
antigen, i.e. cross reactivity between host and foreign antigens or modification of 
host proteins due to infection, drug administration and inflammation etc. 
(Theofilipoulos and Dixon, 1985; Huang et ai, 1988). The second is the genetic 
predisposition for autoimmunity through regulatory failure and the third is the 
triggering with bacterial mitogen of potentially autoimmune B-cell which normally 
held in check by suppressor cells. 
Autoantibodies are commonly regarded as being intrinsically involved in 
the tissue injury associated with autoimmune diseases. Whilst this may be true in a 
number of important examples (e.g. Systemic lupus erythematosus, Goodpasture's 
disease and Myasthenia gravis), this is not true of all autoimmune diseases. For 
example, autoantibodies may form secondary to the tissue damage associated with 
the underlying disease (e.g. cardiac antibodies produced after myocardial 
infarction) (Katsorida and Moutsopoulos, 2001). Autoantibodies may also occur as 
an epiphenomenon to the underlying disease, and whilst in this situation they may 
be a useful marker for the presence or predisposition to certain autoimmune 
processes, they are not in themselves directly contributing to tissue injury. Table 2 
summarizes the most commonly encountered autoantibodies with their disease 
associations. 
Genetic factors in autoimmunity 
Clinicians treating patients of autoimmune disorders have long been struck 
by the findings that these patients frequently have relatives suffering from the same 
or different autoimmune disorders (Shoenfeld and Isenberg, 1989). Several 
chromosomal regions/genes have been defined that could confer generic liability to 
autoimmune diseases (Tsao, 2003). Majority of the genes associated with 
autoimmune diseases, within the major histocompatibility (MHC) class II alleles, 
display various abilities to bind and present peptides to lymphocytes (Marrack and 
Kappler, 2001). Some alleles might be more predisposing to autoimmunity. 
Specific alleles of MHC class II genes have been linked with SLE in ethnic groups, 
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e.g. increased frequency alleles encoding for HLA-DR3 was observed in 
Caucasians and in Japanese lupus patients stronger association with HLA-DR2 
were reported (Hahn, 2005). 
Table 2 
Autoimmune diseases and their respective autoantibodies 
Disease Autoantibodies directed against 
Non-organ speciflc 
Systemic lupus erythemetosus 
Scleroderma 
Sjogren's syndrome 
Mixed connective tissue disease 
Rheumatoid arthritis 
Chronic active hepatitis 
Autoimmune haemolytic anaemia 
Multipule sclerosis and related 
demyelinating diseases 
Organ specific 
Autoimmune thyroid diseases 
Addison's disease 
Pernicious anemia 
Inflammatory bowel diseases 
Primary biliary cirrhosis 
Myasthenia gravis 
Goodpasture's syndrome 
Pemphigus vulgaris 
Bullous pemphigoid 
Insulin dependent diabetes 
Wegener's granulomatosis and other 
vasculitides 
Nuclear antigens, DNA, Sm, Cardiolipin 
Nuclear antigens, Scl-1, Scl-70 
Nuclear antigens SS-A, SS-B 
Extractable nuclear antigen (RNP) 
Fc region of IgG (rheumatoid factor). 
Nuclear antigens 
Smooth muscle antigen 
Red cell membrane antigens 
Myelin basic protein antigen 
Thyroglobulin, Microsomal antigen, TS1 
Aderanal cortical cell antigen 
Intrinsic factor. Parietal cell antigen 
Colonic mucosal antigen 
Mitochondrial antigen 
Acetylcholine receptor 
Glomerular basement membrane 
Epidermal intercellular substance 
Skin basement membrane 
Islet cell antigen (cytotoxic T-cells) 
Serine protease and myeloperoxidase 
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The HLA system plays a major role in the normal functioning of the 
immune system. Hundreds of associations between HLA alleles and autoimmune 
disorders (as well as other diseases) have been found (Shiina et al, 2004). 
Immunological factors in autoimmunity 
The immuno-regulatory network plays major role in the onset and 
development of autoimmune diseases. Abnormality in the immune system causes 
reaction against surface antigens. Role of B- and T-cells and inhibitory molecules 
have been suggested in the initiation of autoimmune diseases although self-reactive 
B- and T-lymphocytes are eliminated during their development in the bone marrow 
or thymus by negative selection, and the process is called central tolerance (Lequn 
and Vassiliki, 2006). B-cells also function as antigen presenting cells (APCs) and 
may present its own antigens, through MHC, to T-cells as foreign bodies. As a 
resuh, the B-cell receives signals from the activated T-cell which induces 
autoantibodies. The abnormal immune response probably depends upon 
interactions among susceptibility genes and numerous environmental factors. In 
wide variety of autoimmune diseases, the regulatory failure results in significant 
decrease in T-suppressor cell members and their activity, thereby unbalancing the 
T-helper/T-suppressor ratio. The increased helper/suppressor ratio has been 
observed in SLE, Sjogren's syndrome. Scleroderma, Rheumatoid arthritis. 
Pernicious anemia. Multiple sclerosis, Immune complex mediated renal diseases, 
Immunologic skin disease etc. Furthermore, immunologic cross reactivity and 
molecular mimicry is an important phenomenon in autoimmune diseases 
(Prinz, 2004). 
Environmental factors in autoimmunity 
Infections agents, medications, chemicals, toxins and ultraviolet light have 
been implicated in autoimmune disorders (Saraux et al., 1999). Ultraviolet light is 
a known trigger for SLE (McGrath, 1999). D-penicillamine and hydralazine, have 
been implicated in the development of SLE and glomeruloephritis (Brik 
et al., 1995). Exposure to mercury could induce lupus like features (Parks and 
Coper, 2005). 
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Rheumatoid arthritis 
It is a chronic systemic inflammatory condition of \mknown cause that 
affects approximately 0.8% of the world population. Rheumatoid arthritis (RA) is a 
multifactorial disease frequently characterized by synovial inflammation usually 
involving peripheral joints, cartilage destruction, bone erosions and subsequent 
joint deformity. The synovium of the inflamed joints is invaded by T-lymphocytes 
expressing an activated genotype and phenotype, as well as neutrophils, 
monocytes, B lymphocytes and dendritic cells (Ruddy et al, 2005). Women are 
more susceptible (three times) to RA than men and the peak incidence is between 
40 and 60 years, but men and women of all ages may be affected. The exact cause 
of RA remains obscure, but it is thought to be triggered and initiated by bacterial 
or/and viral infection(s). Numerous studies on RA patients have revealed increased 
synthesis of endogenous nitric oxide. A number of cells within the joint; including 
endothelial cells of synovial capillaries, mesenchymal cells, neutrophils, 
fibroblasts, lymphocytes, mast cells and macrophages; are able to generate 
substantial quantities of nitric oxide (Van't Hof and Ralston, 2001) which rapidly 
reacts with superoxide radical to give peroxynitrite (Huie and Padmaja, 1993). The 
formed peroxynitrite can be directly cytotoxic else, it can decompose to give 
hydroxyl radical and nitronium ion. Here, it may be pointed out that addition of 
peroxynitrite to biological fluids lead to nitration of aromatic amino acid residues, 
and their presence may be 'marker' of peroxynitrite-mediated (NO - dependent) 
damage in vivo (Kaur and Halliwell, 1994). Overproduction of peroxynitrite may 
be important in the pathogenesis of RA. 
Some investigators have reported a significant correlation between serum 
nitrate and number of tender joints, number of swollen joints and ritchie articular 
index (Onur et al., 2001). Peroxynitrite produced in the inflamed joints may 
contribute to the peri-articular bone-loss observed in RA (Van't Hof and Ralston, 
2001). In many joint diseases, pro-inflammatory factors such as cytokines and 
prostaglandins are released at sites of inflammation along with ROS (Henrotin 
et al, 2003) and nitric oxide (Sakurai et al., 1995). These factors are associated 
with very low concentration of superoxide dismutase in joint fluid (Marklund 
et al, 1986). Studies involving assay of nitrotyrosine residues in synovial tissues of 
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RA patients (Sandhu et al, 2003), or exposure of chondrocytes to synthetic 
peroxynitrite in vitro (Mathy-Hartert et al, 2003) have established that 
combination of superoxide to nitric oxide causes cartilage damage. Studies on 
animal models have revealed that inhibition of peroxynitrite synthesis may have a 
therapeutic role in RA (McCartney- Francis et al, 1993). A traditional herbal 
remedy tripterygium wilfordii Hook F (TWHF) have also been reported to be 
effective in the treatment of rheumatoid arthritis (Wang et al, 2004). The major 
active component of TWHF, triptolide, significantly inhibited nitric oxide 
production in activated peritoneal macrophages and decreased the level of iNOS 
mRNA, suggesting that the specific inhibition of the iNOS gene may be 
responsible for the anti-inflammatory effects of TWHF. Transcription of the iNOS 
gene is activated by pro-inflammatory cytokines such as IL-1 and TNF-alpha 
whereas glucocorticoids are inhibitory, thereafter peroxynitrite generation can be 
inhibited with anti-TNF (by reducing iNOS) as well as directly, by inhibiting iNOS 
activity. 
Furthermore, several studies have confirmed the reduced level of androgens 
and progesterone in RA patients. Men suffering from RA have been reported to 
possess low testosterone, dehydroepiandrosterone and estrone while estradiol, a 
naturally occurring estrogen, was found to be increased which correlated well with 
the inflammatory indices (Tengstrand et al, 2003). Synovial fluids of both male 
and female patients of RA contain significantly high level of estrogen (in 
comparison to androgens) due to increased aromatase activity mediated by TNF-a 
(Cutolo et al, 2006). Not only the increased estrogen level, but also the differential 
expression of estrogen receptors on immune cells might be implicated in the 
pathologic changes seen in the joints of RA patients. Although sex hormones might 
be implicated in the pathogenesis of RA, their role seems much less critical for the 
disease development and flares than in systemic lupus erythematosus. This notion 
is supported by the fact that RA develops predominantly at age 40 and above, and 
that female patients experience remissions during pregnancy when estrogenic 
hormones reach their peak. In collagen induced arthritis (CIA), the disease was 
shown to be accelerated and much more severe in male mice than their female 
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counterparts (Wilder, 1996). Subsequent treatment with estradiol decreased 
inflammatory cytokines (TNF-a and IL-1) and ameliorated the disease activity. 
RA may be accompanied by many autoantibodies in patients' sera. Most of 
these antibodies are not specific for RA because they also occur in other 
inflammatory conditions. Other antibodies appear to be more specific and are, in 
some cases, almost exclusively present in RA. The possible pathogenic nature of 
autoantibodies in RA is still controversial (Smolen and Steiner, 1998). The 
presence of autoantibodies that react with the Fc portion of IgG (rheumatoid 
factor) is currently used as a marker for RA (Tighe and Carson, 1997). However, 
rheumatoid factors have modest specificity (~70%) for the disease. In recent years, 
several newly characterized autoantibodies have become promising candidates as 
diagnostic indicators for RA. Antikeratin (Cordormier et al, 1996), 
anticitruUinated peptides (Schellekens et al, 2000), anti-RA33 (Hassfeld et al, 
1995), anti-Sa (Hueber et al, 1999) and anti-p68 (Blass et al, 2001) 
autoantibodies have been shown to possess >90% specificity. Antinuclear 
antibodies are found in approximately 50% of RA patients (Steiner and 
Smolen, 2002). With the exception of anti-RA33 and antibodies to Epstein-Barr 
virus nuclear antigen, specific antinuclear antibody subsets among patients with 
connective tissue diseases are very rare. Anti-Ro may occasionally be present in 
RA patients, especially if they suffer from secondary Sjogren's syndrome. 
Systemic lupus erythematosus 
It is a multisystem autoimmune disease with protean clinical manifestations 
that may affect any organ or system in human or experimental animals. The 
disease is characterized by flares, remissions and autoantibodies to several 
intracellular and cell-surface antigens. SLE is found worldwide with an estimated 
prevalence of 12-64 per 100,000 populations. The incidence is higher in urban 
populations. In most patients, SLE develops between 15 and 45 years of ages. The 
femaleimale ratio is at least 9:1. In a minority of patients, disease develops after 
the age of 50 years, and in this subgroup the femaleimale ratio is 4:1. 
Numerous investigators have attempted to identify candidate genes in SLE, 
but many implicated genes have not been confirmed. Current evidence suggests a 
role for the HLA region (i) complement components (ii) and IgG receptors (iii). 
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(i) The HLA alleles; Al, B8, DR2 and DR3 have been shown to be associated 
with SLE in Caucasian populations, 
(ii) Deficiencies in classical pathway complement components Clq, C2 and C4 
are strongly associated with the development of a lupus-like disease, 
(iii) IgG receptors on mononuclear phagocyte cells are responsible for clearing 
IgG and IgG-containing immune complex from the circulation. In Afro-
American patients, associations have been found between SLE and the 
presence of low-affinity IgG receptors. 
Multiple autoantibodies, typically antinuclear and anti-DNA antibodies 
characterize SLE (Tan, 1989; Davidson et al, 1990; Steinberg, 1992; 
Harada et al, 1994; Petri, 1996). The clinical manifestations include fever, an 
erythematosus 'butterfly rash' across the face, lesions of discoid lupus or vasculitis 
rash, malar rash, discoid rash, photosensitivity, oral ulcers, non-erosive arthritis, 
pleuritis or pericarditis, anemia, thrombocytopenia, renal, neurologic and cardiac 
abnormalities. One of the impediments in understanding human systemic lupus 
erythematosus has been its marked heterogeneity (Steinberg et al, 1991; 
Steinberg, 1992). Evidence suggests that the initial autoimmune response in SLE is 
restricted to few epitopes (Sing, 2004). The phenomenon of epitope spreading 
offers an explanation for the development of autoantibody specificities to antigens 
that are part of the same molecular complex, such as the close association of anti-
Ro and anti-La antibodies (Weistein et al, 2004). 
The initial immunizing antigens that drive the development of SLE are 
unknown, but characteristics of the immune response in SLE suggest that it is an 
antigen-driven condition. These include oligoclonal expression of antigen-specific 
cells, up-regulation of parallel B- and T-cell responses against the same antigen, 
epitope spreading to progressively more diversified structures on the antigen and 
selection for immune cells with higher affinity for the antigen (Greidinger, 2001). 
Apoptosis play a crucial role in regulation of immune system. Impaired 
apoptosis may be caused by deficiencies in endogenous pro-apoptotic mediators, 
over-expression of endogenous pro-apoptotic mediators or by acquired factors with 
increased risk for the development of SLE. In SLE, the immune system attacks 
various auto-antigens and cause damage in target organs. It has been suggested that 
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dead cells may serve as a repertoire for auto-antigens which can stimulate an 
autoimmune response. 
Role of sex hormones in autoimmunity has been most extensively 
evaluated in SLE patients. The preponderance of SLE in young woman of child 
bearing age with a female to male ratio of 9:1 and the tendency for lupus flares 
during pregnancy and remissions after menopause or cyclophosphamide induced 
ovarian failure; suggest that female sex hormones are crucial regulators of lupus 
activity (Peeva and Zouali, 2005). Hormones influence the sexual dimorphism of 
the immune system. They can initiate or accelerate an autoimmune process and 
thereby contribute to gender biased autoimmune disorders. The female sex 
hormones, estrogen and prolactin, are considered immimomodulators and have 
been implicated in autoimmunity. Not only endogenous estrogens, but also 
environmental estrogens may act in conjunction with other factors to override 
immune tolerance to self-antigens (Peeva and Zouali, 2005). In the B-cell 
compartment, both prolactin and estrogen are immuno-stimulators that affect 
maturation and selection of auto-reactive B-cells, as well as autoantibody 
secretion, while progesterone is an immuno-suppressor. The impact of prolactin 
and estrogen may be based on their capacity to allow auto-reactive B-cells to 
escape the normal mechanisms of tolerance and mature to fully functional 
antibody-secreting B-cells that can cause clinically apparent lupus. However, the 
mechanism of action of the two hormones is different; estrogen leads to the 
survival and activation of auto-reactive B-cells with a marginal zone phenotype, 
whereas prolactin induces self-reactive B-cells with a follicular zone phenotype 
(Grimaldi et al. 2005). 
Deficiencies in the classical pathway of the complement system have been 
implicated in the etiology and pathogenesis of SLE (Liu et al, 2004). Complement 
has both beneficial and deleterious roles in the pathogenesis of SLE. Decreased 
levels of CI, C2, C3a and C4 complement in SLE and their deposition in inflamed 
tissues is suggestive of harmful role of complement in the effectors phase of 
disease. However, homozygous deficiencies of any of the classical pathway 
proteins are strongly associated with the development of SLE. There are two main 
hypotheses to explain these observations. The first invokes unimportant role for 
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complement in the physiological waste-disposal mechanisms of dying cells and 
immune complexes. The second hypothesis is based around the role of 
complement in detraining the activation threshold of B- and T-lymphocytes with 
the proposal that complement deficiency causes incomplete maintenance of 
peripheral tolerance (Manderson et al, 2004). Excessive complement activation as 
a result of a regulator component deficiency leads to tissue injury. Natural 
antibodies and probably autoantibodies present in the sera of patients with systemic 
autoimmune diseases bind to tissues already exposed to damaging insult, activate 
complement and produce pathology (Tsokos and Fleming, 2004). Polymorphisms 
in low affinity IgG (Fey) receptors, which are important for the clearance of 
immune complexes, are also implicated in the pathogenesis of lupus (Salmom 
aal, 1996; Wue/a/., 1997). 
The source of the antigens that drive B-cell responses in SLE is unknown, 
although studies suggest mechanisms by which the self-antigens become 
immunogenic and stimulate responses. In addition to reflecting increased exposure 
to self-antigens, autoantibody responses in SLE may result from abnormalities in 
B-cell signaling and regulation by cytokines (Criscione and Pisetsky, 2003). B-cell 
activation generally requires T-helper cells. T-cells cloned from lupus prone mice 
were found to stimulate the production of anti-DNA antibodies and renal lesion 
when injected. Obligatory and enhanced T-cell help for B-cell has been shown in 
SLE lymphocytes by prolonged expression and co-stimulatory interaction of the 
helper T-cell surface ligand CD40 (CD40L) with B-cell receptor (CD40B) 
(Desai et al, 1996; Koshy et al, 1996). Interaction of CD40L on activated T-cells 
with CD40B cells induces B-cell proliferation and formation of germinal centers. 
Further cell to cell interactions within germinal center lead to B-cell interaction 
through immunoglobulin isotype switching, somatic mutation, clonal expression of 
high affinity B-cells and terminal differentiation to plasma cells (Reiser and 
Stadecker, 1996; Lindhout et al, 1997; Tarlinton et al, 1998). Blockade of 
CD40L has been shown to delay the onset of disease in SLE-prone mice and to 
stabilize or reverse existing renal disease (Mohan et al, 1995; Kalled et al, 1998). 
Further studies in SLE-prone mice showed that an anti-CD40L monoclonal 
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antibody administered to prenephritic mice inhibit both T-cell activation and T-cell 
dependent B cell activation (Huang et al, 2002). 
Peroxynitrite - inflammation nexus 
Inflammation stands in the foreground of a large number of chronic conditions. 
These include rheumatoid arthritis, juvenile chronic arthritis, ankylosing 
spondylitis and systemic lupus erythematosus. Potential biological targets of 
peroxynitrite include membrane as well as cytosolic and nuclear receptors. 
Putative targets of peroxynitrite include epidermal growth factor receptor, the Pi-
and Pa-adrenoceptors (ADRBl and ADRB2), platelet/endothelial cell adhesion 
molecule! (PECAMl), insulin receptor substrate 1 (IRSl) and peroxisome 
proliferator-activating receptor gamma (PPARy) (Pacher et al, 2007). The 
peroxynitrite-mediated oxidation and/or nitration of these receptors may produce 
disturbances in downstream signalling. The reaction of peroxynitrite with 
fibroblast growth factor-1 induces extensive cysteine oxidation, tyrosine nitration 
and irreversible inactivation of protein activity (Bagnasco et al, 2003). 
Peroxynitrite may profoundly influence inflammatory responses at multiple levels. 
During inflammation, which provides a setting that favors the biological formation 
of peroxynitrite, reactions of peroxynitrite with inflammatory mediators such as 
interleukins (ILs) and inducible NOS (iNOS) may provide means for regulating the 
inflammatory response. In contrast to IL-8, peroxynitrite was found to enhance the 
anti-inflammatory function of IL-10 (Freels et al, 2002) and decrease the activity 
of iNOS (Lanone et al, 2002), which could be viewed as a negative-feedback 
mechanism for NO* and peroxynitrite formation during inflammation. In human 
neutrophils, peroxynitrite triggers the down regulation of L-selectin expression and 
the upregulation of CDl lb/CD18 expression (Zouki et al, 2001). These effects are 
likely to be mediated, at least in part, by the ability of peroxynitrite to trigger and 
enhance nuclear factor-KB (NFKB)-mediated pro-inflammatory signal-transduction 
pathways (Matata and Galinanes, 2001) by modifying proteins that are associated 
with the activation of this transcription factor (Bar-shai and Reznick, 2006; Zouki 
et al, 2001; Matata and Galinanes, 2001; Levrand et al, 2005). Additional pro-
inflammatory actions of peroxynitrite may involve its capacity to serve as a 
cyclooxygenase (COX) substrate (Landino et al, 1996), although larger 
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concentrations of the oxidant may inactivate the enzyme (Trostchansky 
etai, 2003). 
Furthermore, peroxynitrite can also contribute to the enhanced production 
of pro-inflammatory mediators by decreasing histone deacetylase-2 (HDAC2) 
activity through nitration (Ito et al, 2004). Overall, elevated local levels of 
peroxynitrite during inflammatory conditions may lead to a deregulation of cellular 
signal-transduction pathways (Levonen et al, 2001), upregulation of localized 
inflammatory stress response and possibly promotion of cellular and tissue injury. 
The upregulation of adhesion receptors by peroxynitrite may also result in an 
increased expression of endothelial adhesion molecules and such cells might 
represent a preferential site for the adhesion and migration of neutrophils when 
high concentrations of nitric oxide and neutrophil-derived superoxide are 
simultaneously present (Sohn et al, 2003). 
Anti-histone autoantibodies in SLE and RA 
Histones are small, highly conserved, extremely cationic and DNA binding 
proteins (Rubin, 1989). They are the major constituent of chromatin and may be 
found in circulation as nucleosomes (Schmiedeke et al, 1989). Autoimmune 
diseases such as systemic lupus erythematosus (SLE), reumatoid arthritis (RA) are 
characterized by autoantibodies reactive to a wide range of nuclear and 
cytoplasmic antigens including DNA, RNA, histones, non-histone proteins, surface 
molecules and intracellular matrix proteins (Theofilopoulos and Dixon, 1981; 
Smolen and Steinberg, 1982). Antinuclear antibodies (ANAs) can penetrate into 
viable cells and interact with nuclear antigens. Indeed, intranuclear 
immunoglobulin may occasionally be found in live circulating Fcy+ mononuclear 
cells from SLE patients or other autoimmune diseases (Fishbein et al, 1979). 
Because the interaction of ANAs with different nuclear antigens in vivo could 
result in different pattern of circulating dysfunction, it seems important to 
determine the clinical characteristics of SLE patients with different antinuclear 
antibodies. Some investigators attribute the diversity of autoantibodies in these 
diseases to generalized (polyclonal) activation of immunoglobulin G-producing B-
cells (Klinman and Steinberg, 1987). Other believe that autoreactive clones are 
specially and preferentially stimulated remain quiescent (Hardin, 1986). 
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Autoantibodies to histones are found in patients with SLE and RA but their 
role in pathogenesis is unclear (Harley et al, 2004). The specificity of 
autoantibodies against HI, H2A, H2B, H3 and H4 histones in SLE have been 
found to be 60, 53,48, 38 and 30 percent respectively (Ghedira et al, 2006; Sun et 
ah, 2008). Antihistone antibodies (AHAs) are among the most prevalent 
antinuclear antibodies most frequently found in drug induced lupus or SLE. 
Because of histones' affinity for glomular basement membrane (Schmiedeke et al, 
1989) and cell surface (Jacob et al, 1989) it has been suggested that histone-
antibody complex might play an important pathogenic role in SLE (Bustos et al, 
1994). Among anti-histone autoantibodies, antibodies to the H2A-H2B complex 
and (H2A-H2B)-DNA complex have been found to be more sensitive and specific 
marker for SLE than autoantidodies to individual histones (Hasegawa et al, 1998). 
Antibodies against histones are heterogenous, some react with the isolated 
histones, other react with DNA-histone complex (Winfield et al, 1978). Optimal 
antibody response to most native proteins requires the interaction of antigen with 
accessory cells, helper T-cells and B-cells (Singer and Hodes, 1983; Julius 
et al, 1982). Although helper T-cells recognize denatured forms of antigen in 
association with class II major histocompatibility complex molecules. B-cells react 
via surface immunoglobulin (Ig) receptors with mostly unprocessed determinants 
(Partanova et al, 1987). It has been indicated that the determinant recognized by 
B-cells are not distributed randomly with particular structural properties 
(Berzofsky, 1985). These are hydrophilic regions present on the outer surface of 
the molecules and are generally not restricted in mobility by secondary intra- or 
inter-molecular interactions. 
For anti-histone antibodies spontaneously produced in SLE, the major 
autoantigenic determinants were mapped to be the amino and carboxyl terminal 
regions of histone (Gohill et al, 1985). Such regions are expected in nucleosome 
core and are preferentially digested when chromatin is treated with trypsin 
(Sollner-webb et al, 1976). On the basis of complement fixation assay, anti-
histone antibodies in patients with systemic rheumatoid diseases are thought to 
occur relatively infrequently and in low titer (Stollar, 1971). Several investigators 
have pointed out that anti-histone antibodies detected by using this assay are 
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present in the least 30% of the patients with idiopathic SLE and 35% of patients 
with rheumatoid arthritis (Aitcheson et al, 1980). Later, it was determined that 
idiopathic SLE sera reacted with all histone (HI, H2A, H2B, H3 and H4), although 
the majority reacted with the bimolecular complex of H2A and H2B 
(Gohill e/a/., 1985). 
Nitrotyrosine in systemic lupus erythematosus and rheumatoid arthritis 
In lupus, a correlation between serum nitrate/nitrite and nitrotyrosine has 
been observed. Although both are measure of nitric oxide production but not 
necessarily correlated with individual patients. Serum nitrate/nitrite is a metabolite 
of nitric oxide and peroxynitrite and is rapidly cleared from the circulation. Thus, 
they reflect systemic peroxynitrite production at that time, similar in a way to 
measures of serum glucose in diabetes. Nitration of tyrosines, however, is 
irreversible and can be detected in in v/vo as nitrated proteins. Serum nitrotyrosine 
levels reflect nitric oxide production over a period of time, perhaps most analogous 
to serum glycated hemoglobin in diabetes (Gilkeson et al, 1998). 
Nitrated renal proteins have been found in murine lupus nephritis, which 
correspond with increase nitrated serum proteins and abnormal staining of nitric 
oxide synthase-2 (N0S2) enzyme in the kidney (Wang et al, 1991). Abnormal 
NOS-2 expressions in keratinocytes and vascular endothelium of lupus patients 
have been observed. Wang et al., 1991 reported increased apoptotic activity among 
renal cells adjacent to those expressing NOS-2 protein. Any or all of above 
mechanisms may contribute to NO-mediated damage in lupus. Free 3-nitrotyrosine 
and serum nitrate/nitrite are rapidly cleared, but protein 3-nitrotyrosine should be 
retained in those subjects without protein urea. However, elevated serum 3-
nitrotyrosine has been seen in subjects with proteinurea despite increased protein 
loss. Thus, serum 3-nitrotyrosine may serve as a measure of protein modification 
by nitric oxide/peroxynitrite (Oates et al., 1999; Hardy et al., 2008). 
Objectives of the present study 
Our major aim was to study the impact of laboratory synthesized 
peroxynitrite on the structure of histones and to test whether the peroxynitrite 
modification had any bearing on the immunogenicity of H2A histone. Structural 
changes were monitored by UV-visible spectroscopy, fluorescence, CD, FT-IR 
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spectroscopy, HPLC and SDS-polyacrylamide gel electrophoresis. 
Immunogenicity was evaluated by injecting native and peroxynitrite-modified 
H2A histones into experimental animals. 
Our second aim was to evaluate the binding profile and specificity of 
naturally occurring autoantibodies in systemic lupus erythematosus and 
rheumatoid arthritis patients with native and peroxynitrite-modified H2A histones, 
with an intention to establish or define the role of peroxynitrite-modified H2A 
histone in systemic lupus erythematosus and rheumatoid arthritis. The antigen-
antibody interaction was studied by direct binding & inhibition ELISA and 
mobility shift assay. 
mmmmammeimmmmxmmmmmmmtmmammmmmmmHmm 
Material 8C Methods 
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MATERIAL 
Calf thymus histones (HI, H2A, H2B and H3), 3-nitrotyrosine, uric acid, 
ascorbic acid, vitamine E, dithiothreitol (DTT), catalase, superoxide dismutase 
(SOD), glutathione (reduced), cysteine, calf thymus DNA, bovine serum albumin 
(BSA), nitrated BSA, anti-human/anti-rabbit IgG-alkaline phosphatase conjugate, 
p-nitrophenyl phosphate, tween-20, coomassie brilliant blue (G-250 & R-250), 
sodium dodecyl sulphate. Freund's complete and incomplete adjuvants, agarose, 
bisacrylamide, 1 -anilinonaphthaJene-8-sulfonic acid (ANS) and Protein-A agarose 
were purchased from Sigma Chemical Company, USA, Milex syringe filters 
(0.45 i^M) were purchased from Millipore Inc., USA. Folin-Ciocalteau reagent was 
purchased from Centre for Biochemical Technology, New Delhi. Silver nitrate, 
formaldehyde, methanol, glacial acetic acid, iso-propanol, sodium chloride, 
sodium carbonate, sodium bicarbonate, magnesium chloride, potassiiun chloride, 
guanidinium chloride, sodium hydroxide, EDTA (disodium salt), hydrogen 
peroxide, sucrose and ammonium persulphate were obtained from Qualigens, 
India. Flat bottom polysorp ELISA modules were purchased from NUNC, 
Denmark. Acrylamide, ammonium persulphate, bisacrylamide, N,N,N',N'-
tertramethylethylenediamine (TEMED) were from Bio-Rad Laboratories USA. All 
other reagents/chemicals were of the highest analytical grade available. 
Collection and processing of blood samples 
Verbal consent of patients as well as healthy subjects was obtained before 
taking blood samples. Also, they were clearly told that the blood samples would be 
used only for the purpose of research. All SLE samples (n=50) used in this study 
were obtained from female patients (in the age group of 35-75 years) attending the 
medicine outdoor clinic and /or those admitted in the medicine ward of the All 
India Institute of Medical Sciences, New Delhi. The patients satisfied the criteria 
of SLE diagnosis established by the American College of Rheumatology 
(Amett et al., 1988) and showed high titre anti-dsDNA autoantibodies by enzyme 
immunoassay. Rheumatoid factor positive sera of arthritis patients (n=50) were 
collected from the Department of Microbiology located in the premises of the 
medical college of Aligarh Muslim University, India. All serum samples were 
decomplemented by heating at 56°C for 30 min. 
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Equipments 
Spectrophotometer (Shimadzu, Japan) with programmable mehing device, 
spectrofluorometer (Shimadzu, Japan), microplate reader, Elico pH meter, 
polyacrylamide gel electrophoresis assembly (Genei, India), table top high speed 
refrigerated ultracentrifuge (Beckman, USA), HPLC-Duo flow (Bio-Rad 
Laboratories, USA), CI8 HPLC column (Supelco discovery), spectropolarimeter 
(Jasco, USA) attached to a microcomputer and FT-IR Spectrometer (Bruker Vector 
22, Germany) were the major equipments used in this study. 
METHODS 
Polyacrylamide gel electrophoresis (PAGE) 
Banding patterns of proteins were analyzed by electrophoresis in 
polyacrylamide gel according to the procedure descried by Laemmli (1970). Slight 
modifications were made in the original protocol only to improve the separation 
and visualization of bands. 
(i) Acrylamide-bisacrylamide (30:0.8):— A stock solution was prepared by 
dissolving 30 gm of acrylamide and 0.8 gm bis-acrylamide in distilled water to a 
final volume of 100 ml. 
(ii) Resolving gel buffer:— A stock solution was prepared by dissolving 
36.3 gm Tris base in 48.0 ml of IN HCl. The contents were mixed, pH adjusted to 
8.8 and the final volume brought to 100 ml with distilled water. 
(iii) Electrode buffer:— 3.03 gm Tris and 14.4 gm glycine were dissolved in 
distilled water and pH was adjusted to 8.3. SDS (1.0 g) was added and volume 
made up to one litre. 
(iv) Procedure for making polyacriamide gel:— Thoroughly cleaned glass 
plates, separated by 1.5 mm thick spacer, were sealed from bottom and sides with 
1% agarose. The resolving gel mixture (10 % ) was prepared by mixing the 
components and poured into the space between the glass plates and allowed to 
solidify. Protein samples mixed with sample dye (10 % glycerol, 2 % SDS, 0.5 M 
Tris pH 6.8 and 0.002 % bromophenol blue) were placed into wells and 
electrophoresis was carried out for 3 to 8 hr at 50-80V (depending on the need). 
The electrophoresed proteins were visualized by staining with silver nitrate. 
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Recipe for 10% resolving gel:— Following solutions were mixed and 
immediately poured between the glass plates. 
Component Volume 
Acrylamide - bisacrylamide 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
3.3 ml 
2.5 ml 
4.0 ml 
0.1ml 
0.1ml 
4.0^1 
SDS-PAGE under non-reducing conditions 
Native and peroxynitrite-modified histones' samples were subjected to 
electrophoresis on 10 % polyacrylamide gel. The samples were mixed with one-
tenth volume of sample dye and electrophoresed at 80 V for 3-4 hr in Tris-glycine 
(pH 8.3) buffer containing SDS. Protein bands were visualized by staining with 
silver nitrate. 
Silver nitrate staining of polyacrylamide gel 
The procedure described by Merril et al., (1981) was followed. Soon after 
electrophoresis, the protein bands were fixed by rapidly immersing the gel in a 
mixture, containing 40% methanol and 13.5% formaldehyde, for 15 min with 
occasional shaking. The gel was then washed with distilled water twice and 
transferred to 0.02% sodium thiosulphate (Na2S203) solution and incubated for 
2 min. Again, the gel was rinsed twice with distilled water. This was followed by 
treatment with 0.1% AgNOa solution for 20 min. The gel was washed with distilled 
water briefly and then immersed in a developer solution (3% sodium carbonate 
solution containing 0.5% formaldehyde and 0.02% Na2S203) for 15 min or until 
the gel was properly stained. The reaction was stopped by transferring the gel to a 
stopper solution (25% isopropanol solution containing 10% glacial acetic acid) and 
left for 5 min. The gel was finally stored in distilled water. 
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Preparation of histone solutions 
Commercially available histones (HI, H2A, H2B and H3) were dissolved 
in phosphate-buffered saline (10 mM sodium phosphate, pH 7.4, containing 
150 mM NaCl) and kept in aliquots at 4°C. As far as possible the histone solutions 
were protected from direct exposure to light. 
Laboratory synthesis of peroxynitrite 
Peroxynitrite was synthesized by rapid quenched flow process 
(Beckman et al, 1996). Briefly, solutions of sodium nitrite (0.6 M in 50 mM 
sodium phosphate buffer, pH 7.4), hydrogen peroxide (0.6 N in 0.7 N HCl) and 
sodium hydroxide (1.2 M in distilled water) were prepared and chilled at 0°C for 
few minutes prior to use. The schematic representation of laboratory ware that 
were assembled to synthesize peroxynitrite is shown in Fig.l. A flow rate of 
10 ml/min was adjusted to get most concentrated solution of peroxynitrite. The 
peroxynitrite was collected in 1.2 M NaOH and kept at -20°C. The concentration 
of stored peroxynitrite was assessed every time it was used; by recording 
absorbance at 302 nm and using molar extinction coefficient of 1670 M"'cm"' 
(Hughes and Nicklin, 1968). 
Modification of histones by peroxynitrite 
The modification was carried out by incubating 25 ^M of histones (HI, 
H2A, H2B and H3) with 100 ^M of diethylene triamine penta-acetic acid (metal 
ion chelator) and 50 ^M, 100 nM and 200 ^M peroxynitrite at 37°C for 30 min. 
The approximate pH of the incubation mixture was in the range of 10-11. 
Spectroscopic analysis of native and peroxynitrite-modified histones 
(a) The absorption spectra of native and peroxynitrite-modified histones were 
recorded on spectrophotometer in the wavelength range of 250-500 nm using 
quartz cuvette of 1 cm path length. 
(b) Fluorescence measurements:— Fluorescence emission was recorded on 
spectrofluorometer. Fluorescence of tyrosine residues of native (control) and 
peroxynitrite-modified histones were monitored in the wavelength range of 
280-400 nm after excitation at 275 nm. Loss in emission intensity was computed 
using the following formula; 
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, ^ Bypass tube 
Fig. 1 Assembly for laboratory synthesis of peroxynitrite. The system was 
operated under vacuum and the bypass tube was initially directed to the waste 
bottle. Once a steady flow was observed the tube was manually twisted to 
collect the peroxynitrite. Barring waste container, all flasks were covered 
with ice. 
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Percent loss _ emission of control histone - emission of peroxynitrite modified histone „ i QQ 
m emission emission of control histone 
Furthermore, fluorescence properties of ANS were utilized to study hydrophobic 
patches in control and peroxynitrite-modified histones. The ANS and histone ratio 
was kept at 1:5 and emission spectra were recorded in the wavelength range of 
400-600 nm after excitation at 380 nm. Increase in fluorescence intensity (FI) was 
calculated as follows; 
FI of peroxynitrite modified histone - FI of control histone 
Percent increase in FI = x 100 
FI of peroxynitrite modified histone 
(cj Circular dichroism (CD) measurements:— Far-UV CD profile of histones were 
recorded on Jasco Spectropolarimeter. The machine was calibrated with D-10-
camphorsulfonic acid and measurements were carried out at 25°C using 
temperature controlled cell holder attached to a Neslab's RTE 110 water bath with 
temperature accuracy of ± 0.1 °C. Control and modified histone solutions (20 |iM) 
were placed in 1 mm pathlength cuvette and profile was recorded in the 
wavelength range of 200-250 nm. A scan speed of 20 nm/min and response time of 
1 sec was chosen to record CD spectra. Four sets of each sample was studied 
under identical conditions to confirm reproducibility of the results. The MRE 
(mean residual ellipticity) expressed in deg cm^ mof' was calculated using formula 
MRE = CD/10 X n X 1 X Cp where CD is in millidegree, n is the number of amino 
acid residues (205 for HI; 129 for H2A; 125 for H2B; and 135 for H3), 1 is the 
path length of the cell and Cp is the mole fraction. Helical content was calculated 
from the MRE values at 222 nm (Chen, et al, 1972) using the equation; 
Percent alpha helix = ^^^^^ xlOO 
I, 30300 ) 
(d) Fourier transformed-infra red (FT-IR) spectroscopy:— Lyophilized samples 
of native and peroxynitrite-modified histones were analyzed on FT-IR 
spectrometer. Briefly, pellets were prepared by mixing lyophilized samples with 
potassium bromide (to absorb remaining moisture, if any) under 5-6 T pressure 
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(produced by carver press) in an attenuated total reflection (ATR) cell attached to a 
thermostat; then the spectra were recorded (Oberg and Fink, 1998). 
Quantitation of nitrotyrosine in pronase digested histones by HPLC 
Pronase digested samples of histones (control as well as those modified by 
different doses of peroxynitrite) were subjected to HPLC analysis for nitrotyrosine. 
The retention time of standard 3-nitrotyrosine was taken as reference for 
comparison purposes. Briefly, the pronase protease was first dialyzed against 
0.1 M sodium acetate buffer, pH 7.2 and added to histone samples (12.5 i^M) 
present in 20 mM Tris buffer (pH 7.4). The pronase: histone ratio was 1:5 (w/w). 
The assay tubes were then kept at 50°C for 16 hr to ensure complete hydrolysis of 
the protein. The hydrolyzed samples were then subjected to ultrafiltration through 
0.42 i^ M Milex filter. The filtrate was diluted 1:2 with eluant buffer 
(0.5 M potassium phosphate, pH 3.0 containing 10% methanol). The material was 
then injected into C-18 reverse phase column (25 cm x 4.6 mm; Vydac, USA) and 
elution was carried out at a flow rate of 0.8 ml/min. The absorbance of eluting 
material was monitored at 274 nm (the A,max of standard 3-nitrotyrosine in eluant 
buffer). 
Identification of nitrotyrosine peak was made on the basis of its matching 
retention time with standard 3-nitrotyrosine and spiking experiments. The 
absorbance of two independent series of known concentration of standard 
nitrotyrosine (dissolved in eluant buffer) was used as reference to determine the 
concentration of nitrotyrosine in samples ( Kaur and Halliwell, 1994). 
HPLC analysis of patients' sera for free nitrotyrosine 
Serum samples of healthy control, SLE and RA patients were first diluted 
1:1 (v/v) with eluant buffer and filtered. The filtrate was injected into C-18 
column. The remaining steps were same as described above. 
Determination of reactive carbonyls in peroxynitrite-modifled histones 
Peroxynitrite mediated oxidation of proteins result in alteration in the side 
chain structure of certain amino acid residues duo to generation of 
2,4-dinitrophenylhydrazine (DNPH) reactive carbonyls. Spectrophotometric assay 
using DNPH reagent can give a quantitative estimate of carbonyl groups in 
proteins. In our studies, protein carbonyls were assayed according to the method of 
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Levine et al, (1994) with slight modifications. Briefly, native and peroxynitrite-
modified histones were precipitated with 10% (v/v) ice-cold trichloroacetic acid 
(TCA). After 10 min incubation at 4°C, the samples were centrifuged at 11,000 x g 
for 3 min. The pellet thus obtained was re-suspended in 0.5 ml of 10 mM DNPH 
dissolved in 2M HCl. The assay tubes were then placed in a sample holder and 
continuously vortexed at room temperature for 1 hr and precipitated with 0.5 ml of 
20% (v/v) TCA followed by centrifugation at 11,000 x g for 3 min. The pellet was 
washed with 1 ml of 1:1 mixture of ethanol-ethyl acetate (v/v) to get rid of any 
extra DNPH reagent. Samples were incubated for 10 min at room temperature and 
then centrifuged at 11,000 x g for 5 min. The supernatant was discarded and the 
pellet was washed twice with ethanol-ethyl acetate mixture. The protein pellet was 
finally suspended in 1 ml of 6 M guanidinium chloride dissolved in 2 mM 
potassium phosphate buffer (pH 2.3, adjusted with trifluoroacetic acid). The 
samples were incubated at 37°C for 15-30 min for complete dissolution of proteins. 
Samples having difficulties going into solution were briefly sonicated and 
incubated at an elevated temperature, up to 70°C. All samples were then 
centrifiiged to remove any insoluble material fi-om suspension. The concentration 
of DNPH was determined by measuring absorbance at 360 nm against guanidinium 
chloride (as blank) using the molar extinction coefficient of 22,000 M"'cm''. 
Histone concentration was determined in the samples from their absorbance at 
276 nm and respective extinction coefficient. Finally, the carbonyl content in 
native and peroxynitrite-modified histones was expressed as nmole/mg of protein. 
Studies on inhibition of nitration 
Effect of certain enzymatic and non-enzymatic inhibitors of nitration were 
evaluated as per the procedure descrived elsewhere (Yoshie and Ohshima, 1997). 
Solutions of histones were pre-incubated with 10 \iM each of dithiothreitol, 
cysteine, glutathione, mannitol, ascorbic acid, vitamine E & uric acid and 500 units 
each of catalase and SOD. After necessary incubation, peroxynitrite was added and 
effect of quenchers on nitration was evaluated with proper control. 
Absorption-temperature scan 
Thermal denaturation of native and peroxynitrite-modified histones 
(dissolved in PBS, pH 7.4) were monitored at 280 nm on spectrophotometer 
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attached with a temperature programmer and controller assembly (Alam et al, 
1993). Percent denaturation of individual sample was calculated using the 
following equation; 
Percent denaturation = "^  ~ °^ X100 
A max-"30 
where, AT is absorbance at different temperatures; Amax is final maximum 
absorbance upon completion of denaturation (95 °C); and A30 is initial absorbance 
at 30 °C. 
Immunization of animals 
Fresh rabbits (1-1.5 Kg) were separately challenged with 200 ng each of 
H2A histone and its peroxynitrite-modified counterparts. The immunogen was first 
complexed with yeast RNA (one-third of immunogen amount) and then emulsified 
with equal volume of Freund's complete adjuvant (first injection). Intramuscular 
injections were given at multiple sites (Bustin and StoUar, 1972). Subsequent 
injections of respective immunogens were given in Freund's incomplete adjuvant 
at weekly intervals. During the course of immunization each animal received a 
total of 1200 \xg of immunogen. A similar course of immunization was followed 
with RNA alone (66.5 ^g). One week after the last dose, marginal ear veins of 
immunized animals were punctured and blood was carefiilly collected. Pre-
immune blood was collected fi-om all animals. Sera were separated and 
decomplemented by heating at 56°C for 30 min. 
Isolation of IgG by Protein A-agrose column 
IgG fi-om human and animal sera were isolated by affinity chromatography 
on Protein A-agarose column. Serum (0.3 ml) diluted with equal volume of PBS 
(pH 7.4) was applied on top of Protein A-agarose column equilibrated with above 
buffer. The wash through was recycled 2-3 times and unbound material was 
removed by extensive washing with PBS. The bound IgG was eluted with 0.58 % 
acetic acid in 0.85 % sodium chloride (Coding, 1978) and collected in a tube 
containing 1.0 ml of 1.0 M Tris-HCl, pH 8.5. Three ml fractions were collected 
and IgG concentration was determined considering 1.4 OD280 = 1.0 mg IgG/ml. 
The isolated IgG was dialyzed against PBS, pH 7.4, and stored at -20°C with 
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0.1 % sodium azide. Elusion profile of one each of human and rabbit serum IgG 
has been given in Fig. 2 (a) &. (b). 
Immunological detection of antibodies 
Pre-immune and immune sera were tested for antibodies against native and 
peroxynitrite-modified histone by enzyme linked immvmosorbent assay (ELISA) 
and gel retardation assay. Furthermore, sera of SLE and RA patients were 
processed in a similar way. 
Reagents for ELISA: Following reagents were used in ELISA; 
Protein coating buffer: 15 mM sodium carbonate, 35 mM sodium bicarbonate, 
pH9.6 
Tris-buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4 
Tris-buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM 
NaCl, 2.68 mM KCl, pH 7.4 containing 500 ^1 Tween-20 per litre. 
Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodiimi 
bicarbonate, pH 9.6 containing 2 mM magnesium chloride. 
Substrate: 500 |ig p-nitrophenyl phosphate per ml of above carbonate-bicarbonate 
buffer. 
ELISA procedure 
ELISA was carried out on flat bottom polysorp modules (AH and 
Alam, 2002). Briefly, polysorp microtitre wells were coated with one hundred 
microlitres of 10 |ig/ml of native/peroxynitrite-modified H2A (dissolved in protein 
coating buffer) and incubated for 2 hr at 37°C and overnight at 4°C. Each sample 
was coated in duplicate and half of the wells served as control devoid of antigen 
only. The antigen-coated wells were emptied and washed thrice with TBS-T to 
remove unbound antigen. Unoccupied sites were blocked with 150 ^1 of 2 % non-
fat dry milk (in TBS, pH 7.4) for 4-5 hr at 37°C and then wells were washed once. 
In direct binding ELISA, sera (1:100 diluted)/purified IgG were directly added into 
antigen coated wells and incubated for 2 hr at 37°C and overnight at 4°C. The 
wells were emptied and extensively washed with TBS-T. Anti-immunoglobulin G 
alkaline phosphatase conjugate (diluted as per manufacturer's instructions) was 
added to each well. The conjugate was incubated at 37°C for 2 hr and then washed 
four times with TBS-T and three times with distilled water. Para-nitrophenyl 
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Fraction number 
Fig. 2 Elution profile of human serum IgG (a) and rabbit serum IgG (b) on 
Protein-A agarose column. Inset: Migration of purified IgG in 7.5% 
SDS-polyacrylamide gel. 
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phosphate was added and final color was read at 410 nm in a microplate reader. 
The results were expressed as mean of difference of absorbance values in test and 
control wells (A^, - ^control)-
Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Alam et al, 2007). Varying amounts of inhibitors (0-20 |ag/ml) were 
mixed with a constant amoimt of patient's sera/antisera or IgG. The mixture was 
incubated at room temperature for 2 hr and overnight at 4°C. The immune complex 
thus formed was coated in the wells instead of the serum/IgG. The remaining steps 
were the same as in direct binding ELISA. Percent inhibition was calculated using 
the following formula; 
Percent inhibition = 1 - "^ '""'"''"^  X 100 
" uniniited * 
Gel retardation assay 
Antigen-antibody specificity was analyzed by mobility shift assay in 
polyacrylamide gel (Khan et al, 2007). Immune complex was prepared by 
incubating constant amount of antigen (native and peroxynitrite-modified H2A) 
with varying amounts of anti-peroxynitrite-modified H2A antibodies for 2 hr at 
37°C and overnight at 4*'C. The reaction mixture was brought to room temperature 
and mixed with one-tenth volume of 0.002% bromophenol blue dissolved in a 
mixture of 0.5 M Tris (pH 6.8), 2% SDS and 10% glycerol. The samples were 
applied into the wells of 10% polyacrylamide gel and electrophoresed at 80 V for 
3-4 hr in Tris-glysine buffer (pH 8.3) containing SDS. Bands were visualized by 
staining with silver nitrate. 
Statistical analysis 
Data are presented as mean ± SD. Statistical significance of control versus 
test was computed using student's Mest (Statgraphics, Origin 6.1). K p value of 
0.05 or less was considered statistically significant. 
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Purity of the commercially available calf thymus histones (HI, H2A, H2B 
and H3) was confirmed by single homogenous band movement in 10% SDS-
polyacrylamide gel (figure not shown). 
Characterization of peroxynitrite 
Peroxynitrite synthesized by rapid quenched flow method was 
identified by its Xmax at 302 nm (Fig. 3) and characteristic yellow color. The 
concentration of peroxynitrite was conveniently assayed by diluting the stock 
into 1.2 M sodium hydroxide followed by absorbance measurement at 302 nm 
using molar extinction coefficient of 1670 M' cm" . 
Use of chemical quenchers to demonstrate generation of peroxynitrite 
Since peroxynitrite is both nitrating and oxidizing agent, its in vitro 
generation was further confirmed by quenchers of nitration and oxidation or 
universal quenchers. The absorbance at 420 nm given by peroxynitrite-modified 
H2A histone was taken as control and effect of various quenchers was evaluated in 
comparison to above control. Uric acid, ascorbic acid, cysteine, dithiothreitol 
(DTT) and vitamin E caused decrease in nitration to the extent of 73, 65, 37, 30 
and 50% respectively. Glutathione, SOD and catalase prevented the nitration to the 
extent of 43, 15 and 20% respectively. Marmitol, a hydroxyl radical scavenger, 
decreased the nitration to the extent of 10% only (Fig. 4). 
Absorption spectroscopy of native and peroxynitrite-modified 
histones 
Pilot experiments were carried out to work out the optimum concentration 
of peroxynitrite needed to modify different histones. Histones (25 ^M each) were 
incubated with varying concentration of peroxynitrite (50, 100 and 200 p,M) and 
subjected to spectrophotometric analysis. As shown in Fig. 5, HI histone gave 
absorbance peak at 276 nm. Upon modification with peroxynitrite the peak at 
276 run kept rising with increasing concentrations of peroxynitrite. Compared to 
276 nm absorbance of HI histone, the hyperchromicities shown by 50, 100 and 
200 i^M peroxynitrite-modified HI histone was 26.3%, 42.8% and 60.0% 
respectively. Although the hyperchromicity shown by 200 nM peroxynitrite-
modified HI was maximum but the peak sharpness at 276 nm has almost vanished; 
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Fig. 3 Absorption profile of peroxynitrite synthesized by quenched flow method. 
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Fig. 4 Effect of some enzymatic and non-enzymatic quenchers on nitration of H2 A 
by peroxynitrite. 
50 
250 300 350 400 450 500 250 300 350 400 450 500 
250 300 350 400 450 
Wavelength, nm 
500 250 300 350 400 450 500 
Wavelength, nm 
Fig. 5 Absorbance profile of native histones ( ) modified by 50 [iM (—A—), 100 |aM 
(—A—) and 200 )iM (—•—) peroxynitrite. 
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a characteristic which could be attributed to severe damage to structure responsible 
for otherwise typical sharpness at 276 nm. Furthermore, the peroxynitrite-modified 
counterparts of HI histone gave birth to a new broad peak centered at 420 nm. This 
new peak was found to be due to generation of nitrotyrosine because a standard 
solution of 3-nitrotyrosine processed under identical conditions yielded similar 
absorbance profile (Fig. 6). 
Under identical conditions and at equimolar concentration, H2A histone 
also gave maximum absorbance at 276 nm. Treatment of H2A histone with 50,100 
and 200 i^M peroxynitrite resulted in hyperchromicity of 276 nm peak to the extent 
of 28.5%, 60% and 66% respectively. Furthermore, for peroxynitrite-H2A it may 
be noted that the sharpness of the peak was almost maintained even at the highest 
concentration of peroxynitrite; an indication that the overall structure of amino acid 
residues responsible for the typical absorbance of H2A at 276 nm is maintained. 
The broader but typical peak at 420 nm is a quasi evidence of progressive nitration 
of tyrosine residues in H2A with changing concentration of peroxynitrite. A close 
analysis of H2B histone and its peroxynitrite counterparts showed similar pattern 
of characteristic 276 nm X^iax and hyperchromicities. However, modification of 
H2B histone with 50 fiM peroxynitrite showed minimum hyperchromicity but the 
sharpness of 276 nm peak was almost maintained at irrespective of concentrations 
of peroxynitrite. The birth of 420 nm peak in H2B after peroxynitrite treatment 
may be attributed to increasing nitration of tyrosine residues in H2B histone. The 
absorption profile of H3 histone and its modified analogs are given in Fig. 5. In 
this case too we observed that the pattern of absorption of peroxynitrite-modified 
H3 analogs at 276 nm and 420 nm were similar. The 276 nm absorbance and 
percent hyperchromicity values of different histones and their peroxynitrite-
modified counterparts are summarized in Table 3. The hyperchromicities seen in 
different histones modified with peroxynitrite is suggestive of structural 
perturbation in histone protein. 
Quantitation of nitrotyrosine in peroxynitrite-modified histone by 
HPLC 
Figure 7 and 8 show HPLC profile of 3-ntrotyrosine taken as standard. We 
observed well defined peaks with a retention time of -12.25 min. The peaks' 
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Fig. 6 Spectrum of standard 3-nitrotyrosine. 
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Table 3 
Absorption data on histones and their peroxynitrite-modifled counterparts 
Histone type UV absorption at 276 nm Percent hyperchromicity 
Hl"^  0.028 — 
0.038" 26.3 
0.049'' 42.8 
0.070' 60.0 
H2A'^ 0.100 — 
0.107' 21.3 
0.268" 60.2 
0.290' 64.2 
H2B^ 0.032 — 
0.040" 20.0 
0.053*' 39.0 
0.070' 54.0 
H3'^  0.086 
0.126" 31.7 
0.225'' 66.2 
0.367' 76.5 
N = Native histone. a, b and c represent corresponding histones treated with 50 jiM, 
100 /iM and 200 ^M peroxynitrite. 
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absorbance was directly proportional to 3-nitrotyrosine concentration as depicted 
in Fig. 9. Analysis of 50 ^M & 100 nM peroxynitrite-modified HI, H2A, H2B and 
H3 revealed generation of nitrotyrosine identified as well defined peaks with a 
retention time of-12.5 min (Figs. 10-13). This matches with the retention time of 
approximately -12.25 min shown by standard 3-nitrotyrosine. HPLC of pronase 
hydrolyzed native histones under identical conditions did not show any peak with 
retention time of-12.5 min (Fig. 10a, 11a, 12a & 13a). It is concluded that the 
presence of nitrotyrosine in modified histones is the result of nitration caused by 
peroxynitrite. The nitrotyrosine content of the modified histones as calculated from 
the calibration curve of standard 3-nitrotyrosine (Fig. 9) has been summarized in 
Table 4. 
Fluorescence spectroscopy of native and modified-histones 
Tyrosine contributes significantly to intrinsic fluorescence of proteins. As 
per the primary structure, there is one tyrosine in HI, three in each of H2A and H3 
and five in H2B histone. The fluorophoric property of tyrosine residue was utilized 
to record the emission profiles of native histones and their peroxynitrite-variants 
after excitation at 280 nm. Emission profile of different histones and their 
peroxynitrite-counterparts are presented in Fig. 14. Irrespective of histone type, the 
fluorescence intensity was maximum at an emission wavelength of 305 nm; a 
characteristic associated with tyrosine. Even the peroxynitrite modification of these 
histones did not alter the wavelength of maximum emission. However, the 
emission intensity kept decreasing with increasing concentrations of peroxynitrite 
which may be attributed to nitration of tyrosine residues in corresponding histones. 
Table 5 depicts emission data on histones in the environment of peroxynitrite. 
ANS (l-anilinonaphthalene-8-sulfonic acid) fluorescence 
Effect of peroxynitrite modification on the hydrophobic clusters in native 
and peroxynitrite-modified histones were probed with ANS. Fig. 15 shows ANS 
fluorescence spectra of peroxynitrite-modified HI, H2A and H2B and H3 histones 
respectively. It appears that the peroxynitrite-modification of above histones has 
gradually exposed the hydrophobic clusters/patches which are available for ANS-
binding as indicated by increase in ANS fluorescence intensities and shift in the 
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Table 4 
HPLC analysis of 3-iiitrotyrosine in native and peroxynitrite-modified liistones 
Histone type fiM of nitrotyrosine 
Hl^ ^ -
0.58' 
l.OO" 
H2A'^ 
1.83* 
5.91'' 
H2B'*' 
0.87" 
H3^ 
1.35' 
5.04*' 
N = Native histone. a and b represent corresponding histone treated with 50 \iM and 100 |xM 
peroxynitrite. 
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Fig. 14 Fluorescence emission profile of native histones ( ) modified with 50 i^M (—A—), 
100 ^M (—A—) and 200 \xM (—•—) peroxynitrite. 
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Table 5 
Fluorescence characteristics of native histones and their modified counterparts 
Histone type 
Hl'^ 
H2A'^ 
H2B^ 
HS"^ 
Intensity (A.U.) 
453 
393' 
353" 
341 ' 
706 
543" 
446" 
214' 
612 
545" 
461" 
361' 
431 
274" 
234" 
122' 
Percent loss in intensity 
after modification 
— 
13.2 
22.3 
24.7 
— 
23.0 
36.8 
69.6 
— 
10.9 
24.6 
41.0 
— 
36.4 
45.7 
71.6 
N = Native histone. a, b and c represent corresponding histones treated with 50 ^M, 
100 ^ iM and 200 \iM peroxynitrite. 
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Fig. 15 Fluorescence emission profile of ANS (—o—) binding to native histones (—) and the 
histones modified with 50 ^M ( - A - ) , 100 i^M (-A-) and 200 ^M ( - • - ) 
peroxynitrite. 
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emission maximum wavelength. The results of ANS binding with native and 
modified histones are summarized in Table 6. 
SDS-polyacrylamide gel electrophoresis of histones 
Histones modified with peroxynitrite were subjected to non-reducing 
polyacrylamide gel electrophoresis under denaturing conditions. Twenty five ng 
each of native and peroxynitrite-modified histones were loaded into the wells of 
10% polyacrylamide gels. The migration patterns of silver stained bands of native 
and peroxynitrite-modified histones are shown in Fig. 16 A-D. The native forms of 
all histones moved as compact single band. Moreover, HI, H2A and H3 histones 
modified with peroxynitrite (50 and 100 |xM) showed retarded migration in the gel. 
Furthermore, it is quite clear that peroxynitrite-induced nitration and oxidation has 
resulted in cross linking of histones vis-a-vis formation of high molecular weight 
species. In case of H2B histone, the peroxynitrite-modified forms did not show 
retardation as observed for other histones under study. Instead, we observed a more 
prominent band in comparison to native H2B. It may be due to binding of more 
silver ions to additional aromatic amino acid residues available after treatment with 
peroxynitrite. During the study it was noticed that histones modified with 200 ^M 
peroxynitrite did not enter the gel and clear cut bands were seen at the top of the 
well (results not shown). It may be concluded that higher concentrations 
peroxynitrite produced large aggregates which failed to enter the gel. 
CD spectroscopy of histones 
Circular dichroic (CD) studies provide rapid determination of proteins' 
secondary structure and thus a usefiil technique for quick assessment of 
conformation. The amide chromophores of the peptide bonds in proteins give CD 
reading in far-UV range (200-250 nm). Proteins rich in alpha-helix give negative 
bands near 222 nm and 208 nm. The circular dichroic profile of pure beta-sheets 
display negative bands near 216 nm and 175 nm and a positive band between 
195-200 nm. The characteristic far-UV CD properties of proteins were exploited to 
look into the secondary structure of different histones and changes there in after 
modification with peroxynitrite. The far-UV CD profile of different histones is 
given in Fig. 17 & 18. The peroxynitrite-modified forms of histones showed 
changes in ellipticity at 222 nm and 208 nm compared to their non-modified 
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Table 6 
ANS-binding characteristics of native and peroxynitrite-modified histones 
Histone type 
Hl"^  
H2A'^ 
H2B^ 
m"^ 
Fluorescence 
intensity (A.U.) 
75.0 
84.0* 
lOO.O" 
108.0' 
239.0 
281.0" 
407.0" 
430.0' 
75.0 
100.0* 
108.0" 
117.0' 
76.0 
108.0" 
139.0" 
173.0' 
(nm) 
490 
483 
481 
480 
490 
472 
468 
468 
490 
482 
480 
480 
490 
480 
478 
475 
Shift in X a^x 
(nm) 
— 
07.0 
09.0 
10.0 
— 
18.0 
22.0 
22.0 
— 
08.0 
10.0 
10.0 
— 
10.0 
12.0 
15.0 
Percent increase in ANS 
binding to modified 
histones 
— 
10.7 
25.0 
30.5 
— 
15.0 
41.0 
45.0 
— 
25.0 
31.5 
36.0 
— 
29.0 
45.3 
56.0 
N =Native histone. a, b and c represent corresponding histone treated with 50 [iM, 100 i^M and 
200 ^M peroxynitrite. 
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B 
HI histone (lane 1) modified 
with 50 & 100 |J.M peroxynitrite 
(lanes 2 & 3) respectively. 
H2A histone (lane 3) modified 
with 50 & 100 |aM peroxynitrite 
(lanes 2 & 1) respectively. 
D 
H2B histone (lane 3) modified 
with 50 & 100 nM peroxynitrite 
(lanes 2 & 1) respectively. 
H3 histone (lane 1) modified 
with 50 & 100 jaM peroxynitrite 
(lanes 2 & 3) respectively. 
Fig. 16 SDS-polyacrylamide gel (10%) of native histones and their 
peroxynitrite-modified variants. Electrophoresis was carried for 4 hr at 
70 volts and the gels were stained with silver nitrate. 
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Fig. 17 Far-UV CD spectra of native HI and H2A histones ( ) modified 
with 50 nM ( ) and 100 nM ( ) peroxynitrite. 
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counterparts. The pronounced negative ellipticities at 208 nm in case of non-
modified histones (except H2B) are indicative of short alpha-helical regions. It 
appears that peroxynitrite modification of histones has destroyed alpha-helical 
content of these basic proteins as reflected by increase in ellipticity values of 
modified conformers. The MRE and alpha helical contents of different histones are 
summarized in Table 7. 
FT-IR analysis of native and 100 fiM peroxynitrite-modified histones 
FT-IR is much more sensitive than CD spectroscopy for studying 
p-structure in proteins, although higher concentrations of sample are required in 
FT-IR experiments. Fig. 19 represents the FT-IR profile of native forms of HI, 
H2A, H2B and H3 histones at pH 7.5. In native forms, the maximum absorbance at 
a particular wavenumber is referred to as amide 1 region. The spectra of 
peroxynitrite-modified histones show significant difference compared to the native 
histones, indicating the structural changes. The most evident change was the 
appearance of a new band near the wavenumbers 1645 (PON-Hl), 1625 (PON-
H2A), 1640 (P0N-H2B) and 1635 (P0N-H3) respectively, which correspond to 
P-sheets. It means that, in contrast to native forms, the peroxynitrite-modified 
histones contain significant amount of p-structure under the given experimental 
conditions. FT-IR spectra permitted quantitative analysis of the secondary structure 
of histones. These results are summarized in Table 8. Analysis of data shows that 
histones modified with 100 pM peroxynitrite possess significant amount of 
P-structure compared to corresponding native histones. 
Quantitation of dityrosine in peroxynitrite-modified histones 
Peroxynitrite reaction with tyrosine residues in proteins generate phenoxyl 
radicals. These radicals then form C-C covalent bond (cross-link or dityrosine) 
between the aromatic moieties of phenolic tyrosine residues. The amount of 
dityrosine in peroxynitrite-modified histones was calculated. Dityrosine is 
characterized by broad peak of absorbance at 330 nm Xmax- The dityrosine content 
in histones modified with peroxynitrite (50, 100 and 200 nM) are summarized in 
Table 9. 
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Table 7 
CD characteristics of native and peroxynitrite-modified histones 
Histone type MR£ Percent alpha-helix 
Hl^ 15853.66 44.6 
13414.64" 36.5 
10365.85" 26.5 
H2A^ 13333.33 36.3 
08205.13" 19.4 
05128.21" 09.2 
H2B'^ 10047.62 25.4 
05952.38" 10.0 
02658.73" 01.1 
H3^ 11481.48 30.2 
08518.52" 20.4 
05296.30" 09.7 
N = Native histone. a and b represent corresponding histones treated with 50 i^M and 100 |iM 
peroxynitrite. 
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Fig. 19 FTIR of native histones ( ) and their corresponding counterparts modified with 
100 ^M peroxynitrite ( ). 
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Table 8 
FT-IR data on native and peroxynitrite-modified histones 
Histone 
Hl-^  
HZA"^ 
H2B'^ 
m"" 
Wavenumber (cm'*) 
1650.63 
1645.17' 
1658.43 
1625.31" 
1656.76 
1635.12" 
1657.56 
1640.17" 
Percent modiflcation loss at each 
native wavenumber (cm') 
— 
12.30 
— 
13.62 
— 
15.60 
— 
16.00 
N = Native histone, and a represent corresponding histone treated with 100 |j,M peroxynitrite. 
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Table 9 
Dityrosine content of histones modified with peroxynitrite 
Histone type ^M of dityrosine 
Hl'^ 
H2A'^ 
H2B'^ 
HS"^  
0.2" 
3.5" 
5.5* 
13.2' 
40.0" 
64.2' 
5.1" 
8.0" 
15.2' 
12.7' 
30.0" 
44.0' 
N = Native histone. a, b and c represent corresponding histones 
treated with 50 i^M, 100 ^M and 200 |iM peroxynitrite. 
76 
Melting studies on native and peroxynitrite-modified histones 
Effect of peroxynitrite-modification on the stability of different histones 
was studied by recording heat induced changes in absorbance values. The mid-
point melting temperature (Tm) was calculated from different absorbance values at 
280 nm in the temperature range of 30-90°C. The thermal denaturation profiles of 
native and peroxynitrite-modified histones are depicted in Fig. 20. We observed 
that treatment of histones with peroxynitrite produced thermal stability as shown 
by increase in the melting temperatures of peroxynitrite-modified samples of 
histones. Formation of cross links and/or disulphide bridge(s) appears to be the 
main reason for increased stability of peroxynitrite-modified histones. Table 10 
summarizes the Tm values of native and modified samples. 
Carbonyl estimation in native and peroxynitrite-modified histones 
Peroxynitrite-mediated protein oxidation may result in cleavage, cross-
linking and modification of amino acid side chains. Carbonylation of lysine, 
arginine, threonine and proline residues are established markers of protein 
oxidation. The carbonyl groups are detected by their derivatization with 
2,4-dinitrophenyl hydrazine. The reaction forms 2,4-dinitrophenyl hydrazone 
which is quite stable and measured spectrophotometrically at 360 nm. 
The carbonyl content in native HI histone was found to be 7.8 nmole/mg of 
protein. Upon modification with 50 ^M, 100 i^M and 200 [iM peroxynitrite, the 
carbonyl content increased to 9.3, 13.7 and 19.0 nmole/mg of protein respectively 
(Table 11). The carbonyl was also estimated in other histones (both in native and 
modified conditions) and the data are summarized in the above table. The data 
simply points out that the formation of nitrotyrosine in histones is increasing with 
change in peroxynitrite concentration, but not without oxidation of the proteins. 
Immunogenicity of native and peroxynitrite-modified H2A histone 
Since H2A histone was found to be maximally nitrated under our 
experimental conditions, we chose only this histone for antibody induction. 
Antisera of animals immunized with native and peroxynitrite-modified H2A 
histone were tested for antibody titre by direct binding immunoassay on polysorp 
wells coated with respective immunogens. 
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Fig. 20 Thermal denaturation profile of native histones (—n—) modified with 50 \iM (—o—) 
and 100 nM (—A—) peroxynitrite. The samples were kept in PBS (pH 7.4) at a 
concentration of 10 ^ M. 
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Table 10 
Melting temperature (Tm) of native and peroxynitrite-modified histones 
Histone type Tm, °C 
Hl"^  60.0 
64.1' 
69.4" 
HIA"^ 55.0 
a 60.0 
64.4" 
H2B'^ 58.7 
a 65.9 
72.5" 
m^ 64.8 
a 70.0 
75.0" 
N = Native histone. a and b represent corresponding histones treated with 
50 \iM and 100 nM peroxynitrite. 
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Table 11 
Carbonyl content of histones modified with peroxynitrite 
jj.. . „„ Carbonyl contents Percent increase in 
Histone type , . , . ^ . . . . 
(nmole/mg protein) carbonyl level compared 
to control 
Hl"^ 7.8 — 
9.3' 16.0 
13.7" 43.0 
19.0' 60.0 
HZA"" 6.0 
8.3' 27.0 
lO.O" 40.0 
14.0' 57.0 
HIB"" 6.9 
9.2' 25.0 
14.8" 53.0 
17.2' 60.0 
H3^ 7.5 
10.0' 25.0 
15.2" 50.0 
21.0' 64.0 
N - Native histone. a, b and c represent corresponding histones treated with 50 |xM, 100 ^M 
and 200 nM peroxynitrite. 
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Antiserum against 50 p,M peroxynitrite-modified H2A showed an antibody 
titre of 1:6400 (Fig. 21c). Modification vsath 100 jaM peroxynitrite conferred more 
immnuogenicity on H2A histone and a titre of > 1:25600 was seen (Fig. 2Id). 
Native H2A induced moderate antibody response (Fig. 21a). Yeast RNA used as 
carrier was non-immunogenic (Fig. 21b). 
Specificity of induced antibodies against 50 ^M and 100 ^M peroxynitrite-
modified H2A with corresponding inmiunogens is shown in Fig. 22 a, b. It was 
observed that the H2A histone modified with 100 |xM peroxynitrite was not only a 
powerfiil immunogen but its antibodies are more specific. Since modification of 
H2A histone by 100 fiM peroxynitrite induced best antibody response, fiirther 
studies were carried out with this antigen and the corresponding antibodies induced 
against it. 
Purification of serum IgG 
Immunoglobulin G was isolated fi-om preimmune and immune sera by 
affinity chromatography on Protein A-agarose column. Protein A (from 
Staphylococcus aureus) binds to IgG fi-om most mammalian species through 
unique histidine residues present on Fc region of the molecule. Purity of IgG 
isolated from each of a rabbit- and human serum is shown by single band 
movement in SDS-polyacrylamide gel under non-reducing conditions (Fig. 2a & 
b and inset there in). 
IgG purified from preimmune serum and antiserum against 100 nM 
peroxynitrite-modified-H2A histone were subjected to direct binding immunoassay 
on microtitre wells coated with 100 ^M peroxynitrite-modified H2A histone. The 
IgG purified from immune serum showed strong binding with the coated antigen 
(Fig. 23). Preimmune IgG showed negligible binding under identitical conditions. 
The specificity of isolated anti-100 |i,M peroxynitrite-modified H2A IgG was 
evaluated by inhibition ELISA using immunogen as inhibitor and coating antigen 
(Fig. 24). The antibody specificity for the immunogen was evident from 93% 
inhibition. Comparison of data in Fig. 22 and Fig. 24 suggest that antigen-antibody 
interaction is more specific with purified IgG. 
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Fig. 21 Direct binding ELISA of antiserum (—•—) against (a) native H2A, (b) yeast RNA (c) 
H2A modified with 50 jxM peroxynitrite, and (d) H2A modified with 100 jxM 
peroxynitrite. The microtitre wells were coated with respective immunogens. Preimmune 
serum binding to corresponding immunogen has been shown by filled squares (—•—). 
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Fig. 22 Inhibition of binding of preimmune (—•—) and immune (—n—) 
serum antibodies by H2A modified by 50 |aM peroxynitrite (a), and 
H2A modified by 100 |.iM peroxynitrite (b). 
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Fig. 23 Direct binding ELISA of affinity purified immune IgG (—A—) and 
preimmune IgG (—A—). The microtitre wells were coated 100 }iM 
peroxynitrite-modified H2A histone. 
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Fig. 24 Inhibition of binding of preimmune (—•—) and immune (—a—) IgG by 
100 |iM peroxynitrite-pmodified H2A. The microtitre wells were coated 
with 100 nM peroxynitrite-modified H2A. 
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Use of anti-100 fiM peroxynitrite-modified H2A IgG antibodies to study 
epitope sharing by other proteins modifled by peroxynitrite 
That the experimentally produced antibodies against 100 ^ iM peroxynitrite-
modified H2A histone are specific has been clearly shown by inhibition studies 
(Fig. 22b and Fig. 24). Native H2A histone used as competitor of anti-100 i^M 
peroxynitrite-modified H2A IgG showed 52% inhibition in antibody binding 
(Fig. 25a). It indicates that not all epitopes typical of native H2A histone have been 
polymerized into neo-epitopes upon peroxynitrite modification. It means 
peroxynitrite-modified H2A histone still has some old epitopes which are scattered 
among neo-epitopes. Therefore, immunization with peroxynitrite-modified histone 
may produce polyspecific antibodies which can recognize both old and neo-
epitopes or altogether there are two types of antibodies, one recognizing nitrated 
neo-epitopes and other binding exclusively with old epitopes. Binding of anti-
100 \iM peroxynitrite-modified H2A IgG antibodies was also carried out with an 
array of peroxynitrite-modified proteins including HI, H2B and H3 histones 
(Fig. 25b,c,d-28). Results of cross-reaction studies have been summarized in 
Table 12. This study suggests that nitrated epitopes of different proteins (or amino 
acids) share common properties. Furthermore, among peroxynitrite-modified 
amino acids, nitrated-tyrosine showed 70% inhibition in antibody binding followed 
by nitrated-phenylalanine and nitrated-tryptophan. Participation of nitrated-
tyrosine (nitrotyrosine) as preferred substrate for anti-100 |j,M peroxynitrite-
modified H2A IgG antibodies points out the significance of nitrotyrosine in 
immunogenicity. 
Gel retardation assay 
Antibody specificity for the immunogen was evaluated by mobility shift of 
antigen-antibody complex in denaturing polyacrylamide gel. Constant amount of 
native H2A histone or peroxynitrite-modified H2A was incubated with varying 
amounts of anti-100 \iM peroxynitrite-modified H2A IgG antibodies for 2 hr at 
37°C and overnight at 4°C. The antigen-antibody complex thus formed was then 
electrophoresed on 10% SDS-polyacrylamide for 4 hr at 80 V and stained with 
silver nitrate. Formation of high molecular mass immune complex with retarded 
mobility was observed (Fig. 29b). Increasing antibody amount has produced 
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Fig. 25 Inhibition ELISA of anti-peroxynitrite-modified H2A IgG antibodies binding by 
different inhibitors. The microtitre wells were coated with peroxynitrite-modified H2A 
histone. 
(a) Native H2A (—D—) and peroxynitrite-modified H2A (—•—). 
(b) Native H2B (—D—) and peroxynitrite-modified H2B (—•—). 
(c) Native H3 (—a—) and peroxynitrite-modified H3 (—•—). 
(d) Native HI (—D—) and peroxynitrite-modified HI (—•—). 
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Fig. 26 Inhibition ELISA of anti-peroxynitrite-modified H2A IgG antibodies binding by 
different inhibitors. The microtitre wells were coated with peroxynitrite-modified H2A 
histone. 
(a) Native human IgG (—•—) and peroxynitrite-modified human IgG (—•—). 
(b) Native tyrosine (—o—) and peroxynitrite-modified tyrosine (—•—). 
(c) Native SOD (—•—) and peroxynitrite-modified SOD (—•—). 
(d) Native HSA (—D—) and peroxynitrite-modified HSA (—•—). 
88 
100 
100 0 100 
a 
o 
••4 
a 
0 
a 
4) 
4) 
eu 
• 
20-
40-
60-
80-
100 
1 11 
1^  ~ °~-—-
• 
1 1 l - T - l . l . I • 
~ °\ 
D 
\ 
\ 
• 
(c) 
100 
0.1 1 10 100 0.1 1 10 100 
Inhibitor concentration, fig/ml Inhibitor concentrat ion, fig/ml 
Fig. 27 Inhibition ELISA of anti-peroxynitrite-modified H2A IgG antibodies binding by 
different inhibitors. The microtitre wells were coated with peroxynitrite-modified H2A 
histone. 
(a) Native catalase (—n—) and peroxynitrite-modified catalase (—•—). 
(b) Native LDL (—a—) and peroxynitrite-modified LDL (—•—). 
(c) Native trypsin (—D—) and peroxynitrite-modified trypsin (—•—). 
(d) Native tryptophan (—•—) and peroxynitrite-modified tryptophan (—•—). 
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Fig. 28 Inhibition ELISA of anti-peroxynitrite-modified H2A IgG antibodies binding by 
different inhibitors. The microtitre wells were coated with peroxynitrite-modified H2A 
histone. 
(a) Native phenylalanine (—D—) and peroxynitrite-modified phenylalanine (—•—). 
(b) Native pDNA (—n—) and peroxynitrite-modified pDNA (—•—). 
(c) Native calf thymus DNA (—a—) and peroxynitrite-modified calf thymus DNA (—•—). 
(d) Native yeast RNA (—D—) and peroxynitrite-modified yeast RNA (—•—). 
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Table 12 
Cross reactions of peroxynitrite-modified H2A IgG antibodies 
Inhibitor Maximum percent inhibition at 
20 ng/ml 
Peroxynitrite-modified H2A 
Native H2A 
Peroxynitrite-modified H2B 
Native H2B 
Peroxynitrite-modified H3 
Native H3 
Peroxynitrite-modified HI 
Native HI 
Peroxynitrite-modified IgG 
Native human IgG 
3-nitrotyrosine 
Tyrosine 
Peroxynitrite-modified SOD 
Native SOD 
Peroxynitrite-modified HSA 
Native HSA 
Peroxynitrite-modified Catalase 
Native Catalase 
Peroxynitrite-modified LDL 
Native LDL 
Peroxynitrite-modified Trypsin 
Native trypsin 
Peroxynitrite-modified Tryptophan 
Native tryptophan 
Peroxynitrite-modified Phenylalanine 
Native phenylalanine 
Peroxynitrite-modified human pDNA 
Native human pDNA 
Peroxynitrite-modified calf thymus DNA 
Native calf thymus DNA 
Peroxynitrite-modified yeast RNA 
Native yeast RNA 
93 
52 
73 
41 
64 
37 
60 
27 
69 
27 
70 
34 
34 
10 
65 
23 
60 
30 
61 
28 
58 
20 
14 
07 
22 
08 
35 
21 
30 
17 
20 
11 
' Wells were coated with 100 ^M peroxynitrite-modified H2A histone. 
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(a) (b) 
Fig, 29 Mobility shift assay of anti-100 p-M peroxynitrite-modified-H2A IgG 
antibodies in SDS-polyacrylamide gel. Electrophoresis was performed 
on 10% gel for 4 hr at 80 Volts. 
(a) Native H2A (25 i^g, lane 1) was incubated with 10, 20, 30, 40 and 
50 |xg of anti-peroxynitrite-modified H2A IgG (lanes 2-6) and 
incubated for 2 hr at 37°C and overnight at 4°C. 
(b) Peroxynitrite-modified H2A (25 |ig, lane 1) was incubated with 10, 20, 
30, 40 and 50 ^g of anti-peroxynitrite-modified H2A IgG (lanes 2-6) 
and incubated under identical conditions. 
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corresponding increase in immune complex as evident from intensity of band. The 
free antigen showed proportional decrease of intensity. The mobility shift results 
indicated that induced antibodies against 100 nM peroxynitrite-modified H2A are 
specific but also recognizing the epitopes on native H2A (Fig. 29a). 
Studies on systemic lupus erythematosus patients 
Direct binding ELISA ofSLE sera with native DNA, native H2A histone 
and 100 ^M peroxynitrite-modified H2A 
All 50 SLE samples included in this study were pre-tested for anti-DNA 
autoantibodies and found to be positive. Age- and sex- matched sera from 
apparently healthy individuals served as control. The sera were diluted 1:100 and 
subjected to direct binding ELISA on microtitre wells separately coated with equal 
amounts of native DNA, native H2A histone and 100 i^M peroxynitrite-modified 
H2A histone (Fig. 30-32). Twenty SLE sera (40%), *labeled, showed higher 
binding with peroxynitrite-modified H2A histone compared to native DNA or 
native H2A histone. No appreciable binding was observed with the pooled sera of 
normal subjects. These observations are important in view of the immunogenic 
nature of peroxynitrite-modified H2A histone and reported incidence of 
hypemitrotyrosinemia and anti-histone antibodies in some SLE patients. 
Enzyme immunoassay of SLE IgG with native DNA, native H2A histone and 
100 fiM peroxynitrite-modified H2A 
IgG were purified from twenty SLE sera which showed higher binding with 
peroxynitrite-modified H2A histone in direct binding ELISA. All SLE IgG were 
first subjected to direct binding assay on microtitre wells coated with 100 .^M 
peroxynitrite-modified H2A. This helped us to work out the amount of IgG 
antibodies required for antigen saturation. The direct binding profile of one SLE 
IgG has been shown in Fig. 33. 
The fine antigenic specificity of isolated SLE IgG was evaluated using 
native DNA, native H2A and 100 ^M peroxynitrite-modified H2A as inhibitors. 
Purified SLE IgG was separately mixed with DNA, H2A and 100 \sM 
peroxynitrite-modified H2A (0-20 ng/ml) and incubated for 2 hr at 37°C and 
overnight at 4°C. The resulting complex was coated instead of only serum/IgG. 
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Fig. 30 Binding of 1:100 diluted SLE sera to native DNA (—•—), native histone H2A 
(—•—) and 100 ^M peroxynitrite-modified H2A (—•—). Pooled normal 
human sera (NH) showed negligible binding with coated antigens. 
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Fig. 31 Binding of 1:100 diluted SLE sera to native DNA (—•—), native histone H2A 
(—D—) and 100 p.M peroxynitrite-modified H2A (—•—). Pooled normal human 
sera (NH) showed negligible binding with coated antigens. 
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Fig. 32 Binding of 1:100 diluted SLE sera to native DNA (—•—), native histone H2A 
(—D—) and 100 ^M peroxynitrite-modified H2A (—•—). Pooled normal 
human sera (NH) showed negligible binding with coated antigens. 
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Fig. 33 Direct binding ELISA of a purified SLE IgG (—A—) and normal human IgG 
(—•—) on microtitre wells coated with 100 |xM peroxynitrite-modified H2A 
histone. 
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The remaining steps were same as described for direct binding ELISA. The 
interaction of inhibitors with different SLE IgG has been represented as percent 
inhibition in antibody binding with coated antigen (Fig. 34-38). The peroxynitrite-
modified H2A histone emerged as the most powerful inhibitor followed by native 
DNA and native H2A. The summary of inhibition studies has been complied in 
Table 13. Inter-comparison of data by a statistical method yielded a p-value of 
<0.001 for peroxynitrite-modified H2A vs native DNA or native histone. This 
points out that the data are statistically significant. The immunogenic nature of 
peroxynitrite-modified H2A (or other protein) and the reported incidence of anti-
histone antibodies and hypemitrotyrosinemia in SLE patients advocates possibile 
role of peroxynitrite-modified protein antigens in SLE initiation in a sub-
population of patients. 
Determination of protein carbonyl content in SLE sera 
Carbonyl contents in 12 SLE sera (no. 2-4, 14-16, 21, 25, 26, 29, 34 and 
42) and 12 normal human sera were determined to assess the effect of in vivo 
oxidative stress in normal subjects and SLE patients. The average carbonyl 
contents of 12 SLE sera was found to be 2.85 ± 0.21 nmole/mg protein compared 
to 1.95 ± 0.20 nmole/mg protein in healthy subjects (Fig. 39). The statistical 
analysis of data revealed that SLE samples had significantly higher content of 
carbonyls {p < 0.05) compared to normal sera. 
Estimation ofnitrotyrosine 
First of all, a proper control was prepared by mixing equal amount of ten 
serum samples of apparently normal human subjects. Fig. 40 represents the HPLC 
chromatogram of pooled control serum. We did not observe nitrotyrosine peak 
(corresponding to -12.25 min retention time) in the control serum. It may be 
recalled that a standard solution of 3-nitrotyrosine processed under identical 
experimental conditions gave a clear cut peak having a retention time of 
-12.25 min (Fig. 7). Results of HPLC analysis of 10 SLE samples are given in 
Fig. 41-45. All samples were positive for nitrotyrosine because we observed 
peaks matching with the retention time of 3-nitrotyrosine. The concentration of 
3-nitrotyrosine in SLE samples were calculated from the calibration curve of 
standard 3-nitrotyrosine and the data are compiled in Table 14. 
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Fig. 34 Inhibition of SLE IgG (isolated from sera 2, 3, 4 and 15) binding by native DNA 
(—A—), native H2A histone (—•—) and 100 ).iM peroxynitrite-modified H2A 
histone (—O—). Microtitre wells were coated with native DNA (2.5 |ig/ml). 
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Fig. 35 Inhibition of SLE IgG (isolated from sera 16, 17, 21 and 22) binding by native DNA 
(—A—), native H2A histone (—•—) and 100 \xM peroxynitrite-modified H2A 
histone (—O—). Microtitre wells were coated with native DNA (2.5 |ag/ml). 
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Fig. 36 Inhibition of SLE IgG (isolated from sera 23, 24, 25 and 26) binding by native DNA 
(—A—), native H2A histone (—•—) and 100 |iM peroxynitrite-modified H2A 
histone (—O—). Microtitre wells were coated with native DNA (2.5 |ag/ml). 
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Fig. 37 Inhibition of SLE IgG (isolated from sera 29, 30, 33 and 34) binding by native DNA 
(—A—), native H2A histone (—•—) and 100 f.iM peroxynitrite-modified H2A 
histone (—O—). Microtitre wells were coated with native DNA (2.5 jxg/ml). 
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Fig. 38 Inhibition of SLE IgG (isolated from sera 35, 42, 49 and 50) binding by native DNA 
(—A—), native H2A histone (—•—) and 100 nM peroxynitrite-modified H2A 
histone (—O—). Microtitre wells were coated with native DNA (2.5 ng/ml). 
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Table 13 
Inhibition of SLE IgG binding by native DNA, native H2A histone and 
100 nM peroxynitrite-modified H2A 
W rf^ 
IgG 
01 (2)* 
02(3) 
03(4) 
04(15) 
05 (16) 
06(17) 
07(21) 
08 (22) 
09 (23) 
10(24) 
11 (25) 
12 (26) 
13(29) 
14 (30) 
15(33) 
16(34) 
17(35) 
18(42) 
19(49) 
20 (50) 
Maximum percent inhibition at 20 p.g/ml 
nDNA 
50.8 
57.4 
56.0 
49.8 
45.8 
46.5 
53.5 
47.0 
45.8 
49.3 
51.7 
54.6 
58.0 
50.0 
44.0 
52.0 
56.0 
58.8 
52.0 
43.2 
nH2A 
25.0 
37.0 
35.0 
38.0 
40.0 
30.0 
33.0 
35.0 
29.0 
37.0 
28.0 
27.0 
33.0 
25.0 
22.0 
31.0 
29.0 
37.0 
41.0 
33.0 
Peroxynitrite-
modified H2A 
72.0 
77.0 
75.0 
67.0 
68.0 
71.0 
76.0 
70.0 
69.0 
70.0 
71.0 
81.0 
80.0 
65.0 
65.0 
83.0 
78.0 
90.0 
63.7 
64.2 
MeaniS.D. (51.11 ±4.75) (32.25 ± 5.32) (72.75 ± 7.13) 
* 
Microtitre plates were coated with native DNA. 
Numbers in parentheses show the corresponding SLE serum number in Fig. 30-32 that was 
used to isolate IgG. 
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NH SLE sera 
Fig. 39 Level of carbonyls in SLE and normal human sera. Each histogram 
represents the mean ± S.D. of 12 samples. 
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Fig. 40 HPLC profile of the pooled control serum. The dov^ Ti head arrow points out the 
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Fig. 41 HPLC profile of SLE serum sample number 2 (a), and number 3 (b). The 
figures have well defined peaks matching the retention time of standard 
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Table 14 
Quantitative estimation of nitrotyrosine in SLE sera by HPLC 
SLE serum sample Absorbance at 274 nm ^M of niytotyrosine 
number 
2 0.78 0.956 
3 0.93 1.261 
4 0.85 1.022 
16 0.68 0.848 
21 0.91 1.217 
26 1.15 1.783 
29 1.00 1.435 
34 1.18 1.826 
35 0.95 1.283 
42 1.23 1.870 
Mean ± SD = (1.35 ± 0.37) ^ M 
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Gel retardation assay of SLE IgG with native and peroxvnitrite-modified 
H2A histone 
Gel retardation assay was employed to visualize and confirm the interaction 
of native and 100 ^M peroxynitrite-modified H2A histone with IgG antibodies 
isolated fi*om SLE sera. A constant amount of native and modified-histone was 
incubated with increasing concentrations of SLE IgG for 2 hr at 37°C and 
overnight at 4°C. The antigen-antibody complex was then electrophoresed on 
10% SDS-polyacrylamide gel for 4 hr at 80 V and stained with silver nitrate. 
Although high molecular mass immune complex with retarded mobility was 
observed with both native and peroxynitrite-modified H2A (Fig. 46 a and b), but 
in case of peroxynitrite-modified H2 A histone we observed increasing number of 
retarded bands with increase in amount of SLE IgG. This difference may be due to 
formation of more than one type of immune complex of different mass in case of 
peroxynitrite-modified H2A. The free antigen showed proportional decrease of 
intensity. 
Studies on rheumatoid arthritis patients 
Direct binding ELISA of rheumatoid arthritis sera with native DNA, 
native H2A histone and 100 /uM peroxvnitrite-modified H2A 
All 50 rheumatoid arthritis samples included in this study were pre-tested 
for rheumatoid factor and found to be positive. Age- and sex- matched sera from 
apparently healthy individuals served as control. The sera were diluted 1:100 and 
subjected to direct binding ELISA on microtitre wells separately coated with equal 
amounts of native DNA, native H2A histone and 100 p,M peroxynitrite-modified 
H2A histone (Fig. 47-49). Sixteen RA sera (32%), ^ labeled, showed higher 
binding with peroxynitrite-modified H2A histone compared to native DNA or 
H2A histone. No appreciable binding was observed with the pooled sera of normal 
subjects. These observations are important in view of the immunogenic nature of 
peroxynitrite-modified H2A histone and reported incidence of 
hypemitrotyrosinemia in good number of rheumatoid arthritis patients. 
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(a) (b) 
Fig. 46 Gel retardation assay of a SLE IgG with native and 100 p.M peroxynitrite-
modified H2A histone in SDS-polyacrylamide gel. Electrophoresis was 
performed on 10% SDS-polyacrylamide gel for 4 hrs at 80 Volts. 
(a) Native H2A (25 ^g, lane 1) was incubated with 20, 30, 40, 60 and 80 ^g of 
anti-peroxynitrite-modified H2A IgG (lanes 2-6) and incubated for 2 hrs at 
37°C and overnight at 4°C. 
(b) 100 nM peroxynitrite-modified H2A (25 |J.g, lane 1) was incubated with 
20, 30, 40, 60 and 80 [ig of anti-peroxynitrite-modified H2A IgG 
(lanes 2-6) and incubated under identical conditions. 
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Fig. 47 Binding of 1:100 diluted RA sera to native DNA (—•—), native H2A histone 
(—a—) and 100 ^M peroxynitrite-modified H2A (—•—). Pooled normal 
human sera (NH) showed negligible binding with coated antigens. 
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Fig. 48 Binding of 1:100 diluted RA sera to native DNA (—•—), native H2A 
histone (—a—) and 100 ^M peroxynitrite-modified H2A (—•—). Pooled 
normal human sera (NH) showed negligible binding with coated antigens. 
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Fig. 49 Binding of 1:100 diluted RA sera to native DNA (—•—), native H2A histone 
(—n—) and 100 p.M peroxynitrite-modified H2A (—•—). Pooled normal 
human sera (NH) showed negligible binding with coated antigens. 
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Enzyme immunoassay of rheumatoid arthritis IgG with native DNA. native 
H2A histone and 100 fiMperoxynitrite-modified H2A 
IgG were purified from sixteen rheumatoid arthritis sera which showed 
higher binding with peroxynitrite-modified H2A histone in direct binding ELISA. 
The purified rheumatoid arthritis IgG were first subjected to direct binding assay 
on microtitre wells coated with 100 |iM peroxynitrite-modified H2A. This helped 
us to calculate amount of IgG antibodies required for antigen saturation. Direct 
binding profile of one rheumatoid arthritis IgG has been shown in Fig. 50. 
The fine antigenic specificity of RA IgG was evaluated using native DNA, 
native H2A and 100 |aM peroxynitrite-modified H2A as inhibitors. Rheumatoid 
arthritis IgG was separately mixed with native DNA, native H2A and 100 nM 
peroxynitrite-modified H2A histone (0-20 ng/ml) and incubated. The resulting 
complex was coated on antigen coated wells instead of only serum/IgG. Interaction 
of inhibitors with various rheumatoid arthritis IgG has been represented as percent 
inhibition in antibody binding with coated antigen (Fig. 51-54). The peroxynitrite-
modified H2A histone emerged as the most powerfiil inhibitor followed by native 
DNA and native H2A. The summary of inhibition studies has been compiled in 
Table 15. Inter-comparison of data by a statistical method yielded a/7-value of 
<0.001 for peroxynitrite-modified H2A vs native DNA or native H2A histone. It 
shows that the data are statistically significant. The immunogenic nature of 
peroxynitrite-modified H2A and reported incidence of hypemitrotyrosinemia in 
rheumatoid arthritis patients suggests that peroxynitrite-induced modification of 
proteins in and around joints might lead to an autoimmune response in a sub-
population of RA patients and immune complex formation may ftirther complicate 
the biochemistry of joints. 
Determination of protein carbonyl in rheumatoid arthritis sera 
Carbonyl contents in randomly selected 12 rheumatoid arthritis sera 
(no. 16-19, 21, 25, 30, 32, 36, 38, 41 and 42) and 12 normal human sera were 
determined. The average carbonyl contents of rheumatoid arthritis sera was found 
to be 3.15 ± 0.21 nmole/mg protein compared to 1.95 ± 0.20 nmole/mg protein in 
healthy subjects (Fig. 55). The statistical analysis revealed that rheumatoid arthritis 
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Fig. 50 Direct binding ELISA of a purified RA IgG (—A—) and normal human IgG 
(—•—) on microtitre wells coated with 100 i^M peroxynitrite-modified 
H2A histone. 
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Fig. 54 Inhibition of RA IgG (isolated from sera 32, 38, 41 and 42) binding by native DNA 
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Table 15 
Inhibition of RA IgG binding by native DNA, native H2A histone and 
100 (iM peroxynitrite-modified H2A 
W^-rf"* 
IgG 
01 (6)* 
02(9) 
03 (15) 
04(16) 
05 (17) 
06(18) 
07 (19) 
08 (21) 
09(23) 
10 (25) 
11 (29) 
12(30) 
13 (32) 
14 (38) 
15(41) 
16(42) 
Maximum 
nDNA 
46.4 
48.0 
49.5 
53.0 
50.0 
40.0 
41.8 
42.0 
46.7 
50.0 
44.0 
47.0 
39.0 
42.5 
50.8 
40.7 
percent inhibition at 
nH2A 
34.0 
34.8 
32.8 
35.0 
32.4 
24.0 
30.7 
31.0 
34.0 
34.8 
28.0 
32.0 
27.0 
31.0 
35.8 
29.0 
20 fig/ml 
peroxynitrite-
modified II2A 
68.0 
70.0 
74.0 
79.0 
74.0 
59.0 
61.0 
63.0 
70.0 
72.0 
68.0 
75.0 
59.0 
67.0 
75.0 
65.7 
Mean ± S.D. (45.71 ± 4.35) (31.64 ± 3.30) (68.73 ± 6.05) 
" Microtitre plates were coated with native DNA. 
Numbers in parentheses show the corresponding RA serum number in Fig. 47-49 that was 
used to isolate IgG. 
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Fig. 55 Level of carbonyls in rheumatoid arthritis and normal human sera. Each 
histogram represents the mean ± S.D. of 12 samples. 
125 
samples had significantly higher content of carbonyls (p < 0.05) compared to sera 
of healthy subjects. 
Determination ofnitrotyrosine in rheumatoid arthritis sera 
First of all, a fresh control was prepared by mixing equal amount of ten 
serum samples of apparently normal human subjects. Fig. 56 represents the HPLC 
chromatogram of pooled control serum. Nitrotyrosine peak (corresponding to 
-12.25 min retention time) was not seen in the control serum. Results of HPLC 
analysis of 10 rheumatoid arthritis samples are given in Fig. 57-61. Nitrotyrosine 
was detected in all samples because we observed peaks matching with the retention 
time of standard 3-nitrotyrosine. Amount of 3-nitrotyrosine in rheumatoid arthritis 
sera was calculated from the calibration curve of standard 3-nitrotyrosine and the 
data are presented in Table 16. 
Gel retardation assay of rheumatoid arthritis IgG with native and 
peroxynitrite-modified H2A histone 
Once again we employed gel retardation assay to visualize and confirm the 
true interaction of IgG, purified from RA patients' sera with native and 100 ^M 
peroxynitrite-modified H2A histone. A constant amount of native and modified-
histone was mixed with increasing concentrations of RA IgG and incubated. The 
resulting complex was then electrophoresed on 10% SDS-polyacrylamide gel for 
4 hr at 80 V and stained with silver nitrate. Results shown in Fig. 62 demonstrate 
that IgG antibodies purified from RA serum is recognizing both old (present on 
native H2A) and new epitopes (appeared after peroxynitrite modification). In case 
of native H2A, the increasing amount of IgG antibodies appears to have initially 
produced immune complex of almost similar size which later marginally increased 
in size as reflected by corresponding decrease in amount of unbound antigen. 
Incubation of RA IgG antibodies with peroxynitrite-modified histone generated 
immune complex of different size and mobility and the unbound antigen showed 
matching decrease. In this case, it seems that both old and new epitopes co-existing 
on peroxynitrite-modified histones are being recognized by IgG antibodies, and 
thus immune complex of large size have been observed. 
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Fig. 56 HPLC profile of the pooled control serum. The down head arrow points out the 
absence of nitrotyrosine in the control which otherwise appears at this retention 
time. 
1 » -
\m 
I H -
< 
«»-
4 » -
(a) 
-1 1 r 
127 
3-iiitrot3rro8lne i 
— J 1 1 1 1 1 1 1 1 1 1 r 
s» itn nit too 
i » -
i i t -
• « » 
(b) 
3-nitrotyrosine 
1 1 1 1 1 1 1 1 j 1 1 \ 1 ] r 
SK lao) DU too 
Retention time, min 
Fig. 57 HPLC profile of RA serum sample number 4 (a), and number 6 (b). The figures 
have well defined peaks matching the retention time of standard 3-nitrotyrosine. 
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figures have well defined peaks matching the retention time of standard 
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Table 16 
Quantitative estimation of nitrotyrosine in RA sera by HPLC 
Rheumatoid arthritis Absorbance at 274 nm )iM of niytotyrosine 
serum sample number 
4 0.56 0.674 
6 0.67 0.815 
14 1.12 1.739 
16 0.98 1.392 
17 0.87 1.065 
23 0.75 0.913 
25 0.81 0.978 
30 0.93 1.348 
38 0.62 0.772 
42 0.52 0.652 
Mean ± SD = (1.035 ± 0.35) jiM 
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(a) (b) 
Fig. 62 Gel retardation assay of an IgG isolated from rheumatoid arthritis serum 
with native and peroxynitrite-modified H2A in SDS-polyacrylamide gel. 
Electrophoresis was performed on 10% SDS-polyacrylamide gel for 4 hrs 
at 80 Volts. 
(a) Native H2A (25 ng, lane 1) was incubated with 20, 30, 40, 60 and 80 ng of 
anti-peroxynitrite-modified H2A IgG (lanes 2-6) and incubated for 2 hrs at 
37°C and overnight at 4°C. 
(b) 100 \iM peroxynitrite-modified H2A (25 \ig, lane 1) was incubated with 
20, 30, 40, 60 and 80 ^g of anti-peroxynitrite-modified H2.A IgG 
(lanes 2-6) and incubated under identical conditions. 
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Nitric oxide (NO) is an endothelium derived gaseous molecule. 
Chemically, it is a free radical but participates in numerous physiological 
processes; neurotransmission, blood pressure regulation, defense mechanism, 
smooth muscle relaxation and immunity (Archer, 1993; Alderton et al, 2001; 
Bergendi et al, 1999; Forstermann et al, 1998). Action of nitric oxide synthase on 
arginine produces NO* and citrulline (Ghafourifar and Cadenas, 2005). 
Furthermore, ubisemiquinone formed at the ubiquinol oxidation center of the 
cytochrome bcj complex is one of two sources of electrons for superoxide 
formation in mitochondria (Dr6se and Brandt, 2008). Cells of the immime system 
produce both superoxide anion and nitric oxide during oxidative burst triggered by 
inflammation. In such situations nitric oxide and superoxide ion may combine to 
produce peroxynitrite (0N00~) which causes oxidation and nitration in 
biomolecules (Carr et al, 2000). Peroxynitrite reactivity towards proteins, lipids, 
amino acids, nucleic acids etc. account for its complex chemistry (Ducroig 
et al, 1999). Because of its oxidizing nature it can directly react with electron rich 
groups; such as sulfhydryl (Redi et al, 1991b), ion sulfer centres (Castro 
et al, 1994), zinc-thiolates (Crow et al, 1995) and active site sulfhydryl in 
enzymes (Takakura, et al, 1999). Peroxynitrite can also produce novel products 
such as nitrotyrosine, nitrotryptophan and nitrated lipids. Thus, this intermediate 
can produce oxidative and nitrosative damage in biomolecules, which in turn may 
lead to autoimmune- and age-related diseases (Drew and Leeuwenburg, 2002; 
Oates and Gilkeson, 2006). Systemic lupus erythematosus (SLE) is an autoimmune 
multifactorial disease of unknown etiology. It is characterized by presence of 
circulating and tissue-fixed autoantibodies to a variety of self and non-self antigens 
including native DNA, histones, non-histone protein antigens and protein-nucleic 
acid complex. Like SLE, the trigger for rheumatoid arthritis (RA) remains obscure. 
Inflammation of the synovial membrane of diarthrodial joints along with 
rheumatoid factor characterizes RA. Rheumatoid factor is an autoantibody that 
reacts with Fc portion of the IgG and serves as an immunological marker in RA. 
Other autoantibodies have also been reported in RA but they lack specificity. 
Histones are small cationic proteins which bind DNA. They are weak 
immunogen probably due to their conserved nature. Histones are major constituent 
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of cells' chromatin and remain confine to nucleus. However, after apoptosis they 
may appear in circulation as nucleosomes. Incidence of autoantibodies against HI, 
H2A, H2B, H3 and H4 histones in sera of SLE patients are 60, 53, 48, 36 and 
29.5% respectively (Ghedira et al., 2006). 
In this study, aqueous solutions of HI, H2A, H2B and H3 histones were 
exposed to laboratory synthesized peroxynitrite and the structural changes have 
been analyzed by physico-chemical techniques. Inhibition of nitration and 
oxidation by reactive nitrogen- and reactive oxygen species inhibitors confirmed 
the generation of peroxynitrite. 
Native structures of HI, H2A, H2B and H3 histones showed a single peak 
having maximum absorbance at 276 nm. With increasing concentration of 
peroxynitrite the 276 nm peaks of histones showed hyperchromicity. This might be 
due to increasing nitration of tyrosine residues which ultimately enhances the 
molar absorptivity compared to native histones (Sokolorsky et al., 1966). 
Furthermore, appearance of a new peak in peroxynitrite-modified histones appears 
to be due to generation of nitrotyrosine because a standard solution of 
3-nitrotyrosine had matching profile. Moreover, appearance of yellow color in 
peroxynitrite-modified histones strongly substantiates the formation of 
nitrotyrosine which gave absorption peak at 420 nm. HPLC analyses of 
peroxynitrite-modified histones confirmed the presence of nitrotyrosine in samples 
because one of the peaks had almost similar matching retention time as shown by 
standard 3-nitrotyrosine. 
Chromophoric groups like tryptophan, tyrosine and phenylalanine 
contribute significantly to intrinsic fluorescence of proteins. But in case of histones 
only tyrosine residues are involved in intrinsic fluorescence because histones lack 
tryptophan, and phenylalanine is a weak chromophore as well as fluorophore. The 
fluorophoric property of tyrosine was taken into account in order to analyze the 
effect of peroxynitrite-mediated nitration of tyrosine. The modified histone 
samples exhibited fluorescence quenching compared to native histones. The 
quenching appears to be the consequence of introduction of nitro group in 
tyrosine's phenolic ring (Uversky el al., 2005). 
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Native unfolded proteins with their unique combination of ordered structure 
(little or nil) under physiological conditions represent a distinct subdivision of the 
protein kingdom (Uversky et al., 2000). A combination of overall low 
hydrophobicity and large net charge is a characteristic property of histone proteins. 
Peroxynitrite-modified histones' partially folded structures were characterized by 
availability of exposed hydrophobic clusters to which ANS had showed binding. 
This interaction resulted in a considerable increase in the ANS fluorescence 
intensity and a pronounced blue shift of emission maxima in comparison to native 
histones. Moreover, the large blue shift in the ANS fluorescence maxima reflects 
nitration induced transformation in histones from the natively unfolded state to a 
partially folded structure. Native histones are found in unfolded state due to their 
low hydrophobicity but as a result of peroxynitrite modification the positive 
charges are neutralized and this favors exposure of more hydrophobic clusters inter 
alia binding of ANS. 
Histones structural modification was ftirther confirmed by far UV-CD 
spectroscopy. The far UV-CD spectra of native histones under our experimental 
conditions were foimd to be typical of significantly unfolded proteins. Upon 
modification with peroxynitrite, the histones showed increase in ordered structure 
compared to native histones. This was manifested by an increase in the negative 
ellipticity around 222 rmi which is taken as the measure of ordered secondary 
structures (Munishkina et al., 2004). The above changes were ftirther substantiated 
by FT-IR spectroscopy. The main advantage of FT-IR in comparison to CD is that 
the FT-IR is much more sensitive to P-structures (Oberg and Fink, 1998). We 
recorded the FT-IR (amide 1 region) spectra of native and 100 ^M peroxynitrite-
modified histones. The most prominent change that we observed was the decrease 
of band intensity at higher wavenumber which correspond to the disordered 
conformation accompanied by the appearance of a new band in the vicinity of 
lower wavenumber, which corresponds to ordered or P-sheet structure. Thus the 
results of CD and FT-IR may be considered as proof that after modification with 
peroxynitrite histones show more ordered structures than native histones. 
Peroxynitrite-induced structural changes in histone were visualized in gel. 
The results threw ftirther light on the substantial structural changes that occurred in 
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histones upon peroxynitrite modification. Formation of inter- and intra- molecular 
cross-links does appear during nitration of histones with peroxynitrite 
(Glazer, 1976) and cross-linking & oligomerization have been reported during 
nitration of several proteins (Lundblad and Noyes, 1984). A marked retardation in 
the mobility of peroxynitrite-modified histones compared to corresponding native 
forms (except for H2B histone) suggest generation of high molecular weight 
species due to cross-linking. For H2B, the peroxynitrite-modified form did not 
show any retardation. However, we observed thickness of bands and that may be 
due to binding of more silver ions to additional aromatic amino acid residues that 
might have been exposed after treatment with peroxynitrite. 
Generation of tyrosyl radical by peroxynitrite and its subsequent reaction 
with another tyrosyl radical (on same or different molecule) may form 
O-O'-dityrosine covalent cross links. To provide additional support to cross-
linking mechanism, we estimated dityrosine content in peroxynitrite-modified 
histones by absorption measurements (Ischiropoulos and Al-Mehdi, 2005). The 
data suggest formation of more dityrosine in H2A, H2B and H3 as compared to HI 
histone and therefore cross-linking and dityrosine may be inter-connected. Melting 
studies demonstrated that interaction of histones with peroxynitrite resulted in 
stability of peroxynitrite-modified histones compared to native histones because 
melting temperature was raised. Here, we would like to point out that our results 
have indicated that nitration leads to formation of partially folded structure from 
natively unfolded form and therefore rise in melting temperature is fully justified. 
Carbonyl content is the most commonly used marker of protein oxidation 
(Shacter, 2000) and accumulation of protein carbonyl has been reported in many 
human diseases (Heal, 2002). During our modification studies, carbonyl content of 
histones increased upon treatment with different doses of peroxynitrite. Since 
peroxynitrite is both an oxidant and a nitrating agent, the increase in carbonyl 
content may be attributed directly to oxidative action of peroxynitrite. 
Histones are conserved proteins and weak immunogens. However, these 
proteins show strong immunogenicity after acetylation and nitration 
(Muller et ai, 1987). It has been suggested that alteration in amino acids structure 
or sequence may generate neo-epitopes on self proteins leading to autoaggeressive 
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immune attack. Furthennore, autologous proteins may also become immunogenic 
if they are structurally modified. These modifications may generate or mask 
antigenic epitopes and that may stimulate relevant B-cells and /or T-cells leading 
to breakdown or bypass of tolerance. 
In rabbits, the peroxynitrite-modified H2A histone was found to be a 
potent immunogen as revealed by high titre antibodies. The induced antibodies 
were immunogen specific but showed cross-reaction with non-modified H2A 
histone. Hence, immunization with peroxynityrite-modified H2A produced 
polyspecific antibodies which could recognize both old and neo-epitopes or 
altogether there are two types of antibodies, one recognizing nitrated neo-epitopes 
and another binding exclusively with old epitopes. Antigenic specificity of purified 
immune IgG was confirmed by inhibition ELISA. More than 90 percent inhibition 
in binding of anti-peroxynitrite-modified H2A histone antibodies with immunogen 
(as inhibitor) is a clear evidence of specificity. 
Cross-reaction studies on anti-peroxynitrite-modified H2A histone 
antibodies with an array of nitrated proteins suggest recognition of common 
antigenic epitope on nitrated proteins. And that common epitope may be 
nitrotyrosine. Furthermore, we found that induced antibodies showed binding with 
H2B, HI, H3 histones, HSA, proteins rich in tyrosine residues and nucleic acids. 
Visual detection of interaction between immune IgG and the immunogen was 
facilitated by gel retardation assay. The results reiterated specificity of induced 
antibodies towards immunogen. Anti-peroxynitrite-modified H2A histone 
antibodies did not show appreciable binding with the native H2A histone in gel. It 
may be said that induced antibodies are predominantly directed against the 
antigenic determinants generated as a consequence of peroxynitrite modification of 
H2A histone. 
Autoantibodies against intracellular proteins and nucleic acids are 
serological hallmark of the systemic rheumatic disease such as SLE, Progressive 
systemic sclerosis (PSS), Sjogren's syndrome (SS), Mixed connective tissue 
diseases (MCTD) and Polymyositis (PM) (Shoenfeld et al, 1989). Each of these 
diseases is identified by the unique autoantibodies. Antibodies to dsDNA serve as 
an immunological marker for the diagnosis of SLE (Su et al, 2007). These 
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autoimmune diseases are associated with multiple antinuclear antibody 
specificities, suggesting a role for both generalized as well as antigen-specific 
immune abnormalities in their etiology (Pisetsky, 1992; Herrmann et al, 1995). 
The peroxynitrite derived species causes extensive damage to proteins and may 
render them immunogenic. 
Despite decades of expansive research work on SLE, the exact nature of 
antigen stimulus for SLE initiation and progression remains unknown. We 
attempted to investigate the binding characteristics of naturally occurring SLE anti-
DNA autoantibodies to native calf thymus DNA and native & peroxynitrite-
modified-H2A histone so that some light could be thrown on the possible role of 
peroxynitrite-modified H2A histone in SLE. Sera of SLE patients, having high titre 
anti-DNA antibodies, showed preference for peroxynitrite-modified H2A histone 
compared to native H2A histone or native DNA. This suggests that peroxynitrite-
modified H2A histone is an effective inhibitor of native DNA-anti-DNA antibody 
interaction. Band shift assay and inhibition ELISA with SLE IgG substantiated the 
preferential binding of peroxynitrite-modified H2A histone with SLE 
autoantibodies. It may be interpreted that nitration of tyrosine residues resulted in 
generation of neoantigen(s) with explicit immune response compared to native 
H2A histone. The body's immunosurveillance may prove ineffective if the 
generation of peroxynitrite is enhanced tremendously, as seen in chronic 
inflammation and in injured tissues. Once peroxynitrite level increases, the damage 
and nitration would be inevitable and the immunoregulatory network would be 
activated to deal with this alien nitration and modification. The subsequent 
production of autoantibodies would be natural step. Separation and quantitation of 
3-nitrotyrosine in SLE sera were carried out by HPLC. The SLE sera showed high 
level of free 3-nitrotyrosine which was not present in control subjects. We 
observed that nitrotyrosine level in SLE sera had a good correlation with disease 
severity (Gates et al., 1999). Thus, measurement of nitrotyrosine may be a useful 
way of determining peroxynitrite-mediated pathology and testing the effectiveness 
of therapeutic agents in preventing such diseases. Cellular metabolism and 
ionization radiation produces both reactive nitrogen & oxygen species. These 
radicals and their subsequent intermediates may react with cellular 
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macromolecules and induce a variety of chemical alterations leading to 
autoantibodies (Rasheed et ai, 2007). The oxidation of a protein typically results 
in increase in carbonyl contents. The increase in carbonyl has been attributed to 
oxidation of lysine, arginine, proline or other amino acid residues. In short, protein 
carbonyl groups are the biomarker of oxidative stress (Dalle-Dome et al., 2003). In 
human plasma, all amino acids in protein are susceptible to oxidative modification 
by hydroxyl radical and hypochlorous acid (Levine et al., 1994). In SLE, reactive 
nitrogen intermediates are over produced due to over expression of inducible nitric 
oxide synthase (iNOS) which may lead to tissue injury and increase carbonyl 
groups in a sub-group of SLE patients. The mechanism through which 
peroxynitrite can be pathogenic in the setting of SLE is through the generation of 
neo-epitopes on self antigens. Serum from SLE patients exhibited increased 
binding to peroxynitrite-modified H2A histone compared to native DNA or native 
H2A histone. This suggests that peroxynitrite modification of self antigens can 
generate neo-epitopes with increased binding affinity over native antigens. 
Rheumatoid arthritis (RA) is characterized by inflammation of the synovial 
membrane of diarthrodial joints. Lack of a specific marker antibody is particularly 
true for rheumatoid arthritis. Rheumatoid factor (RF) is an autoantibody that reacts 
with the Fc portion of IgG and serves as one of immunological marker for this 
disease. A number of additional autoantibodies have been reported in RA patients 
including antibodies to filaggrin, citrullin, keratin, components of the spliceosome, 
anti-nuclear antibodies etc. (Pisetsky, 1992; Herrmann et al, 1995). Nitrotyrosine 
has emerged as a stable end product and marker of inflammation and reactive 
nitrogen species production (Oates et al, 1999). Sera of RA patients having high 
titre rheumatoid factor were analyzed for autoantibodies against native DNA and 
native & peroxynitrite-modified H2A histone. All sera of RA patients showed 
enhanced binding with peroxynitrite-modified H2A histone compared to native 
H2A histone or native DNA. Separation and quantitation of 3-nitrotyrosine in 
randomly selected RA sera were carried out by HPLC. All tested samples of 
rheumatoid arthritis had significantly higher level of nitrotyrosine compared to 
normal healthy subjects. Here also, we observed direct correlation between disease 
severity and nitrotyrosine level. Our results are in conformity with eariier 
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observation that peroxynitrite or its intermediates might be a mediator of joint 
damage in chronic inflammatory joint diseases because permeability increases in 
rheumatoid arthritis (Levick, 1981; Khokha et al, 2003). This may encourage 
nitration of protein tyrosine followed by immune response to the neo-antigens. The 
present study demonstrates that autoantibodies against nitrotyrosine might be 
helpful in monitoring the progress of disease from mild to chronic stage and 
preventive measures, like controlling the excessive production of RNS, could be 
exercised in time. Furthermore, level of nitrotyrosine in combination of other 
clinical features of the RA might be a powerful diagnostic tool. 
Finally, it may concluded that histones modified by laboratory synthesized 
peroxynitrite showed gross structural changes as revealed by physico-chemical 
results. Peroxynitrite-mediated nitration and oxidation appears to have generated 
highly immunogenic epitopes on H2A histone because rabbits challenged with 
peroxynitrite-modified H2A produced high titre antibodies. Furthermore, the 
immunogenicity of peroxynitrite-modified H2A was directly proportional to 
nitrotyrosine contents. Experimentally produced antibodies against peroxynitrite-
modified H2A were polyspecific because they showed specificity for the 
immunogen as well as cross-reaction with nitrated epitopes of other proteins 
modified by peroxynitrite. The preferential binding of peroxynitrite-modified 
histones by autoantibodies derived from SLE and RA sera points out the role of 
oxidatively modified and nitrated proteins in the initiation/progression of SLE and 
RA, at least in a sub-group of these patients. Moreover, oxidatively modified and 
nitrated protein antigens, rather than nucleic acid antigens, appear to be more 
suitable as trigger for these disease because of abundance of tyrosine rich proteins 
in circulation as well as in synovial membrane. 
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